PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [6] : **A61K 38/17**	**A1**	(11) International Publication Number: **WO 95/34316** (43) International Publication Date: 21 December 1995 (21.12.95)

(21) International Application Number: PCT/FI95/00344

(22) International Filing Date: 13 June 1995 (13.06.95)

(30) Priority Data:
258,862   13 June 1994 (13.06.94)   US

(71)(72) Applicants and Inventors: JALKANEN, Markku [FI/FI]; Rauvolantie, FIN-20760 Piispanristi (FI). MALI, Markku [FI/FI]; Inkereentie 176, FIN-24280 Salo (FI).

(74) Agent: ORION CORPORATION; Orion-Farmos, Research & Development, Patent Service, P.O. Box 65, FIN-02101 Espoo (FI).

(81) Designated States: AM, AT, AU, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KG, KP, KR, KZ, LT, LU, LV, MD, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SUPPRESSION OF TUMOR CELL GROWTH BY SYNDECAN-1 ECTODOMAIN

(57) Abstract

Methods of reducing tumor growth by providing the ectodomain of syndecan are provided.

BEST AVAILABLE COPY

-1-

SUPPRESSION OF TUMOR CELL GROWTH BY SYNDECAN-1 ECTODOMAIN

FIELD OF THE INVENTION

This invention is in the field of cancer biology and therapy.
5   Specifically, the invention is to a method for slowing or normalizing the
growth rate of a cell, especially a malignant cell, by providing efficacious
amounts of the ectodomain part of syndecan-1 to such cell. The method
of the invention facilitates and results in the normalization of the growth
rate and differentiation state of malignant cells.

10   ## BACKGROUND OF THE INVENTION

Cellular differentiation is based on selective use of genetic
information programmed by extracellular stimuli, which for example
could include cellular interactions and binding of extracellular effector
molecules by cell surface receptors. It is becoming more evident that
15   cell surface proteoglycans play an important role in the regulation of cell
behavior. Syndecans are cell surface proteoglycans, which have been
shown to participate in both matrix recognition and growth factor binding
and thus believed to participate in cell regulation. The sequences of
human, mouse, rat and hamster syndecans are known. Syndecans have
20   recently been reviewed (Jalkanen, *et al.*, in *Receptors for Extracellular
Matrix*, J. MacDonald & R. Mecham, Editors, Academic Press, San
Diego, pp. 1-37 (1991) and Bernfield, O., *et al.*, *Annu. Rev. Cell Biol.*
8:365-393 (1992)).

Syndecan-1 is the best characterized cell surface proteoglycan
25   (Saunders *et al.*, *J. Cell Biol. 108*:1547-1556 (1989); Mali *et al.*, *J. Biol.
Chem. 265*:6884-6889 (1990)). International patent application WO
90/12033 discloses the aminoacid sequence and corresponding cDNA
sequence of mouse syndecan-1 molecule. A diagnostic method for
detecting transformed cells by detecting changes is the syndecan
30   expression in transformed cells is described in International Patent
Application WO 92/13274 and WO 93/05167.

-2-

The enhancer element of the syndecan gene as well as a method of decreasing the growth of malignant cells by inducing the expression of syndecan within malignant cells is described in International Patent Application (PCT/FI93/00514)

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is the sequence of human syndecan-1. Circles: possible GAG attachment sites; bold underline: transmembrane domain; light underlining: aataa polyadenylation signal.

Figure 2 is the sequence of mouse syndecan-1.

Figure 3 Schematized structure of the core proteins of wild type, tail-less and ecto transfection constructs. The wild type construct contains the full length mouse syndecan-1 ectodomain (Mali, M. et al., J. Biol. Chem. 268:24215 (1993)). The tail-less construct was generated using oligonucleotide-directed mutagenesis resulting a deletion mutant with single arginine residue in the cytoplasmic domain as described in the examples (Miettinen, H.M. et al., J. Cell Sci. in press (1994)). The ecto construct was also derived by oligonucleotide-directed mutagenesis as described in the examples, and has a stop codon in the protease sensitive site just adjacent to the cell surface. Vertical lines indicate putative GAG attachment sites and arrows the dibasic protease sensitive site.

Figure 4 Actin filament organization and immunofluorescence localization of syndecan-1 on the cell surface.

Figure 5 Amount of secreted ectodomain of syndecan-1 from the conditioned medium of Ecto cell clones (Ecto 15, 34, 2 and 23). Cells were cultured for two days in the presence of 10 nM testosterone and the ectodomain of syndecan-1 that accumulated in the medium was used. The culture medium was used directly. Samples were normalized for cell number and equivalent amounts slot-blotted on Hybond-N+ membrane. The ectodomain of syndecan-1 was detected by enhanced chemiluminescence method using 281-2 as described in the examples (Miettinen, H.M. et al., J. Cell Sci. in press (1994)). Quantitations were

-3-

done using computer image analysis system (Imaging Research Inc.). Means and SEMs of two parallel samples are presented.

Figure 6 Actin filament organization of Ecto cell clones. Ecto cells were cultured in the presence of 10 nM testosterone and actin
5   filaments were visualized by rhodamine-conjugated phalloidin.

Figure 7 Soft-agar colony formation of Ecto cell clones. Cells were cultured 12 days in 0.33% soft-agar, DMEM+5% FCS with 10 nM testosterone as described earlier (Leppä, S. *et al., Proc. Natl. Acad. Sci. USA 89*:932 (1992)).

10   **Figure 8** The effect of DEAE-isolated syndecan-1 ectodomain (examples) from the conditioned medium of Ecto 2 cells on growth of NMuMG and testosterone treated (10 nM) S115 cells (S115+). 1500 cells were transferred into 96-well culture plates and cells were cultured with DEAE-isolated syndecan-1 ectodomain until control (without
15   syndecan-1 ectodomain) cells reached about 75-85% confluence (NMuMG cells four days, S115+ three days). Then cells were fixed with 2% paraformaldehyde, stained with 0.5 % crystal violet and washed with distilled water. Stained cells were suspended in 10% acetic acid and spectrophotometrically measured at 595 nm.

20   **Figure 9** The effect of heparitinase treatment of DEAE-isolated syndecan-1 ectodomain on growth inhibition of S115+ cells. S115 + cells were cultured with 1 nM DEAE-isolated syndecan-1 from cultured medium of Ecto 2 cells and from the medium of NMuMG cells, or with the same preparations pretreated with heparatinase (Seikagaku Kogyo Co.)
25   1 hour at 37°C.

Figure 10 The effect of immunopurified syndecan-1 ectodomain on growth of S115+ and NMuMG cells. DEAE-isolated syndecan-1 ectodomain was further purified with 281-2 immunoaffinity column (examples). S115+ and NMuMG cells were cultured with 1 nM
30   immunoaffinity purified syndecan-1 ectodomain.

Figure 11 DEAE-isolated syndecan-1 ectodomain but not HS or CS GAGs inhibit growth of S115+ cells.

-4-

Figure 12 Growth inhibition of different cell line cells (CarB, MCF-7, S115+ with 10 nM testosterone, S115- without testosterone, NIH 3T3, NMuMG and HaCaT) by 1 nM DEAE-isolated syndecan-1 ectodomain (examples). Cell growth were analyzed in all panels similarly as in panel (A) and it was compared to the cells without treatments (% of control, y-axis). Means and SEMs from two parallel samples are presented.

Figure 13. Suppression of tumor growth in nude mice by syndecan-1 ectodomain.

SUMMARY OF THE INVENTION

The present invention is first directed to a pharmaceutically acceptable composition containing syndecan ectodomain.

The invention is further directed to a method for decreasing or normalizing tumor cell growth by providing such syndecan ectodomain protein to a tumor cell, in the cell's extracellular environment.

The methods of the inventions are useful with both malignant and non-malignant tumor cells, and are especially useful with tumors characterized by loss of syndecan-1, such as gliomas, myelomas, carcinomas, sarcomas, lymphomas or adenomas.

DEFINITIONS

In order to provide a clearer and more consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

Cell growth. By "cell growth" is meant cell replication, or the rate of cell division, both controlled and uncontrolled. Therefore, cell growth is the rate of division and replication.

Malignant. By "malignant" is meant uncontrolled cell growth.

More Differentiated Phenotype. In stating that a cell has a "more differentiated phenotype" is meant that the cell possesses a phenotype

-5-

usually possessed by a certain cell type more differentiated than the cell.
A phenotype can be defined by one or more phenotypic characteristics.
For example, an epithelial cell shape is a more differentiated phenotype
of a mesenchymal-like shape; therefore, in this example, the "more
5   differentiated phenotype" is the epithelial cell morphology, rather than a
mesenchymal-like shape. A terminally differentiated mesenchymal cell is
a "more differentiated phenotype" than a condensing mesenchymal cell.
The state of the actin-containing cytoskeleton can also be used;
disorganized actin filaments are indicators of a less differentiated
10   phelotype than organized filaments.

Efficacious Amount. An "efficacious amount" of an agent is an
amount of such agent that is sufficient to bring about a desired result,
especially upon administration of such agent to an animal or human. An
efficacious amount of syndecan-1 ecdodomain in the compositions and
15   methods of the invention is the amount sufficient to reduce tumor cell
growth, preferably to normal growth rates for the specific cell types.

Administration. The term "administration" is meant to include
introduction of the syndecan ectodomain according to the invention into
an animal or human by any appropriate means known to the medical art, ·
20   including, but not limited to, injection, oral, enteral, transdermal and
parenteral (e.g., intravenous) administration.

Exposure to syndecan ectodomain. By "exposing" a cell to
syndecan ectodomain in the compositions of the invention is meant that
the external milieu of the cell is provided with amounts of syndecan   ·
25   ectodomain that are efficacious in promoting the desired effect, generally
a lowered growth rate of a tumor cell.

Pharmaceutically Acceptable Salt. The term "pharmaceutically
acceptable salt" is intended to include salts of the syndecan ectodomain
of the invention. Such salts can be formed from pharmaceutically
30   acceptable acids or bases, such as, for example, acids such as sulfuric,
hydrochloric, nitric, phosphoric, etc., or bases such as alkali or alkaline
earth metal hydroxides, ammonium hydroxides, alkyl ammonium
hydroxides, etc.

-6-

Pharmaceutically Acceptable Composition. The term
"pharmaceutically acceptable composition" is intended to include
solvents, carriers, diluents, and the like, which are utilized as additives or
vehicles to preparations of the syndecan ectodomain of the invention so
5   as to provide a carrier or adjuvant for the administration of such
compounds to patients (human or animal) in need of the same. Such
additives can perform certain functions, such as, for example, provide
the proper ionic conditions for administration, stabilize the syndecan
ectodomain against inactivation or degradation, and/or increase the half-
10   life of the syndecan ectodomain. A pharmaceutically acceptable
composition is medically compatible with the host to which it is being
administered.

Treatment. The term "treatment" or "treating" is intended to
include the administration of the pharmaceutically acceptable
15   compositions of the invention comprising efficacious amounts of
syndecan ectodomain of the invention to a patient for purposes which
may include prophylaxis, amelioration, prevention or cure of a medical
disorder, including the suppression of tumor growth.

Substantially Free of Natural Contaminants. A material is said to
20   be "substantially free of natural contaminants" if it has been substantially
purified from materials with which it is normally and naturally found
before such purification and those contaminants normally and naturally
found with the substance *in vivo* or *in vitro* are substantially absent from
the final preparation of the material. When administered to a subject in
25   need of treatment, the syndecan ectodomain of the invention is
substantially free of natural contaminants which associate with the
syndecan ectodomain either *in vivo* (in the host from which the
ectodomain was isolated), or *in vitro* (as a result of a chemical
synthesis). By "substantially absent" is meant that such contaminants are
30   either completely absent or are present at such low concentrations that
their presence (1) does not interfere with the desired therapeutic effect of
the active agent (herein the abiltiy of the syndecan ectodomain to inhibit
tumor growth) in the therapeutically acceptable composition when such
composition is administered to a patient in need of same and (2) does
35   not harm the patient as the result of the administration of such
composition.

-7-

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention is the discovery that the ectodomains of the syndecans possess certain biological functions and are capable of providing such functions to cells when presented to the external surface
5 of a cell other than the cell that synthesized such syndecan ectodomain. Syndecans are membrane bound proteins. It was surprisingly found that extracellularly-provided syndecan ectodomain, by itself, is sufficient to restore a more differentiated morphology to tumor cells and to suppress the growth of malignant cells. The invention herein is exemplified with
10 syndecan-1.

All syndecans contain a cytoplasmic domain, a transmembrane domain and an extracellular domain. The extracellular domain is the ectodomain. As discussed by Jalkanen, *et al.,* in *Receptors for Extracellular Matrix,* J. MacDonald & R. Mecham, Editors, Academic
15 Press, San Diego, pp. 1-37 (1991)), the syndecans show highly conserved homologous sequences at three separate regions of their ectodomains. A dibasic sequence is immediately adjacent to the N-terminal end of the hydrophobic transmembrane domain, suggesting that it is located next to the outer leaflet of the plasma membrane, and
20 may serve as a protease-susceptible site, which enables the ectodomain to be cleaved intact from the cell surface.

The core protein of human syndecan-1 contains 310 amino acid residues. There is a high degree of structural and functional homology between mouse and human syndecan-1. Human syndecan-1 has an
25 identical size, charge, buoyant density and GAG composition to that of mouse syndecan-1. Human syndecan-1 ectodomain, like that of the mouse, binds to type I collagen fibrils and fibronectin but not to laminin or virtronectin.

The sequence of human syndecan-1 is known and it has been
30 cloned (Mali *et al., J. Biol. Chem. 265*:6884-6889 (1990)). When numbered according to Figure 2 in Mali *et al., J. Biol. Chem. 265*:6884-6889 (1990), amino acids 1 to 251 are the ectodomain of human syndecan-1 (with the secretion-signal attached), the hydrophobic membrane-spanning domain contains the next 25 amino acid residues

-8-

(amino acids 252-276), and the cytoplasmic domain contains the last 34 amino acid residues (amino acids 277-310).

The signal peptide sequence is the first 17 amino acids of the ectodomain. Although useful to promote secretion of syndecan-1 from a
5 cell synthesizing the same, the secretion signal is not necessary for the tumor growth suppression or differentiation functions of the ectodomain of the invention.

Therefore, the sequence of the ectodomain of the invention included those fragments of syndecan amino acid residues 1-251 that
10 retain the GAG attachments sites and desired function of the ectodomain, such as, for example, ectodomains having amino acids 1-251 (with secretion signal and cleaved at the RK site), 18-251 (minus secretion signal but cleaved at the RK site), 1-231 (with secretion signal but cleaved at the RR site) and 18-251 (minus secretion signal but
15 cleaved at the RR site). An ectodomain having a carboxy terminal at a site anywhere between amino acid residues 231-251, or a secretion signal fragment of less than amino acids 1-17 is also useful since those embodiments would be expected to retain the biological properties of the ectodomain.

20 Although the human and mouse ectodomains are only 70% identical at the amino acid level, all putative glycosaminoglycan (GAG) attachments sites are identical between the mouse and human sequences. The five possible glycosaminoglycan attachment sites of human syndecan ectodomain are at positions 37, 45, 47, 206 and 216.
25 Two of these sites belong to the consensus sequence SGXG and three others to (E/D)GSG(E/D). Also identical between mouse and human syndecan are the single site for N-glycosylation and the proteinase-sensitive dibasic RK site adjacent to the extracellular face of the transmembrane domain. Human syndecan also contains a second
30 dibasic RR sequence just 18 residues apart from the RK sequence. Proteolytic cleavage at this site would also release an ectodomain of the invention that contained all GAG sites intact.

The transmembrane domains of human and mouse syndecan-1 are 96% identical (the only change in human syndecan is an alteration

-9-

of an alanine to a glycine) and the cytoplasmic domains are 100% identical in mouse and human syndecan.

Syndecan ectodomain, such as human syndecan ectodomain, can be produced by recombinant techniques in any desired host.

5   However, it is preferable, but not necessary, to utilize a host that is of a similar cell type to that of the tumor, so as to provide as similar GAG composition as possible, to that of the cell in its non-tumor state. Many deposited cell lines that are human tissue specific or characteristic of different cell types are available.

10   For example, the mouse syndecan-1 clones of the invention were constructed using liposome transfection and geneticin to subsequent select stably transfected cells clones. S115 cell line clones (see Fig. 3) expressing either the wild type mouse syndecan-1 (wild type), a deletion mutant with a single arginine residue in the cytoplasmic domain only

15   (tail-less) or the plain ectodomain of syndecan-1 (ecto). Wild type syndecan-1 and cytoplasmic deletion mutant (tail-less) were cloned into EcoRI site of the pBGS eucaryotic expression vector. The ectodomain construct was cloned into pMAMneo vector, in order to obtain efficient expression levels also in the presence of hormone since the MMT LTR

20   promoter is induced by the same steroid hormone as the cells. It is not necessary to use this vector as many such expression vectors are known in the art. Syndecan-1 expression at the cell surfaces was detected using a monoclonal antibody, exemplified using previously described mAb 281-2, that recognizes the ectodomain of mouse syndecan-1 core

25   protein, and actin filaments were visualized using rhodamine-conjugated phalloidin, as an indication of the differentiation state and growth state of the cell.

Without testosterone, S115 cells exhibit organized actin filaments typical to these cells when epithelioidal. In the presence of testosterone,

30   actin was disorganized and globular, and the cell surface expression of syndecan-1 was also suppressed. Wild type and Tail-less clones expressing syndecan-1 at the cell surfaces restored actin filament organization in spite of the testosterone treatment. Because transfection of Tail-less mutant also induced similar changes as the Wild type

35   syndecan-1, S115 cells were transfected with the plain ectodomain and

-10-

more than 50 independent clones secreting different levels of the
ectodomain into the culture medium were produced. The cell surfaces of
these cells stained only faintly for syndecan-1 but still these cells
revealed well organized actin filaments and an epitheloid morphology.
5   These results indicate that ectodomain of syndecan-1 is sufficient
enough to restore epithelioid morphology of testosterone treated S115
cells to that of the more differentiated phenotype and is a useful anti-
cancer drug.

In non-tumor cells, syndecan is expressed in epithelial cells,
10   mesenchymal cells, pre-B cells and plasma cells, but not by B cells.
Syndecan is also expressed in tissues that contains cells of this type,
including human brain tissue. Therefore the methods of the invention are
especially useful against tumors of the epithelial, mesenchymal, pre-B
and plasma cells. Most especially, the methods of the invention are
15   useful in slowing the growth of steroid responsive tumors, especially
estrogen or androgen responsive tumors (tumors that grow better in the
presence of steroids, estrogn, or androgens as indicated) including
breast cell tumors, endometrium cell tumors, and tumors of the prostate
cells.

20   For treatment of humans and animals, syndecan-1 ectodomain is
administered in a pharmaceutically acceptable solution at levels
sufficient to restore the normal growth state of tumor, or malignant cells,
as evidenced by a slower growth rate. The syndecan-containing
pharmaceutically acceptable solution can be administered in any form
25   that effects prophylactic, palliative, preventative or regressive tumor
growth.

The amount of the syndecan ectodomain-1 compositions of the
invention that is administered to the patient, and the duration of such
administration, can be determined by monitoring tumor growth in the
30   patient during the course of the administration, and adjusted according
to the response of the patient. The syndecan ectodomain of the invention
is preferably provided to the target tumor cell at extracellular
concentrations about 0.7 nM-1 nM (see Figure 11), but any
concentration sufficient to decrease growth of the tumor may be used.
35   The ectodomain can be provided either locally (as with a concentrated

-11-

delivery right to the targetted organ) or systemically (such as delivery through the blood stream). The dose of syndecan given to the patient (either human or animal) will therefore take into account the volume (such as blood volume) into which the ectodomain is being

5   administered, and the type of tumor that is being targeted. For example, if a continuous exposure to the syndecan ectodomain is necessary, then more frequent dosages will be required than if only a transient exposure of the tumor to the syndecan ectodomain is necessary. For example, a 1 nM amount of syndecan ectodomain having amino acids 1-251

10   corresponds to 0.2 mg/L (200 µg/L), either in the blood or locally concentrated at the site of action. Typical systemic doses of syndecan ectodomain useful in the methods of the invention for treatment of humans or animals include amounts that provide a final blood concentration of most preferably 0.2 mg syndecan ectodomain per liter

15   blood. Blood volume in humans is 6% of the body weight, hence a 70 Kg person has about 4.2 liters of blood. However, because the effects of the syndecan ectodomain are presumably local (e.g. acting at a specific cell membrane), sequestered or kinetically determined, the theoretically minimum dose can be adjusted upward in order to achieve favorable

20   therapeutic effects.

Syndecan ectodomain may be administered by any route that delivers efficacious levels of the drug to the desired active site, for example, by injection. For parenteral administration, preparations containing the syndecan ectodomain may be provided to a patient in

25   need of such treatment in combination with pharmaceutically acceptable sterile aqueous or non-aqueous solvents, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil, fish oil, and injectable organic esters. Aqueous carriers include water, water-alcohol solutions, emulsions or

30   suspensions, including saline and buffered medical parenteral vehicles including saline and buffered medical parenteral vehicles including sodium chloride solution, Ringer's dextrose solution, dextrose plus sodium chloride solution, Ringer's solution containing lactose, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers,

35   electrolyte replenishers, such as those based upon Ringer's dextrose and the like.

-12-

The syndecan ectodomain containing medicament (the pharmaceutically acceptable solution containing the therapeutically active syndecan-1 ectodomain) can be administered by means of catheters or pumps, especially when it is desired to deliver the

5   ectodomain at localized high concentrations. The syndecan-1 ectodomain-containing medicament can be administered subcutaneously or directly into soft tissue by means of implantaion devices inert to body fluids. Such devices and implantation systems are known in the art. A ceramic sytem for delivery proteins is described, for

10   exmaple, in WO 92/00109.

The syndecan-1 ectodomain containing medicament can be administered by providing such molecule as a part of a chimeric molecule (or complex) which is designed to target specific organs, for example, as part of an antibody that recognizes determinants on the

15   target tissue or organ or cell, in its tumor or nontumor state.

The pharmaceutically acceptable solution contining the sydnecan-1 ectodomain can be administered topically. Although syndecan-1 ectodomain can be administered to a patient in a regime that includes other cancer fighting drugs, optimal administration of the

20   syndecan-containing compositions of the invention are especially useful in this regard.

Topical adminsitration is preferably accomplished in one of two ways. First, the therapeutically active syndecan ectodomain can be mixed with suitable pharmaceutially acceptable carriers and (optionally),

25   penetration enhancers to assist in the delivery of the active agent across the skin, to form ointments, emulsions, lotions, solutions, creams, gels or the like, and the preparation itself is then applied to a certain area of skin. Alternatively, the therapeutically active syndecan ectodomain can be incorporated into a patch or transdermal delivery system according to

30   known technology for the preparation of such patches and delivery systems.

Administration in a sustained-release form is more convenient for the patient when repeated injections for prolonged periods of time are needed, or when continuous exposure of the tumor cell to the

ectodomain is desired. In intravenous dosage forms the compositions of the present invention have a sufficiently rapid onset of action to be useful in the acute management of tumor growth.

Administration may be localized directly to the cell if the cell is
5   associated with a tissue or bodily organ, or administration can be systemic, in a medium in which the cell is found, such as the blood or cerebrospinal fluid. Systemic administration throughout the patient's body, for example, by administration to the bloodstream, facilitates treating patients for whom tumor cells may be at more than one site in
10 the body.

Providing syndecan ectodomain as the product of a syndecan ectodomain expression construct that secretes ectodomain in efficacious amounts is also considered "administration." For example, administration across the blood brain barrier can be achieved by
15 utilizing known viral vector systems to deliver syndecan ectodomain DNA in a manner that expresses ectodomain and secretes it to the extracellular environment, such as, for example, in the retroviral systems described in WO 93/03743, WO90/09441, Breakefield, X.A. *et al.*, *The New Biologist 3*:203-218 (1991) and Huang, Q. *et al.*, *Exp. Neurol.*
20 *115*:303-316 (1992).

The pharmaceutically acceptable composition of the invention, containing the syndecan-1 ectodomain can be manufactured in a manner which is in itself known, for example, by means of conventional mixing, dissolving, lyophilizing or similar processes. The compositions
25 of the present invention that provide the syndecan-1 ectodomain find utility in their ability to slow or prevent tumor growth or tumor reappearance, and in their ability to alter the phenotype of the cell to that a more differentiated state, in both human and animal patients. The syndecan-1 ectodomain compositions of the invention utilize the body's
30 own mechanisms for promoting differentiation of specific cell types to its maximum potential.

The compositions and methods of the invention are not meant to be limited to syndecan-1. Syndecan-1, syndecan-2, syndecan-3 and syndecan-4 are known to contain similar domain structures. It is known

-14-

that differentiation of certain cell types is associated with the loss of syndecan-1 but with the appearance of another member of the syndecan family (Bernfield, O., *et al., Annu. Rev. Cell Biol. 8*:365-393 (1992)). For example, when bronchial epithelia form buds, lung mesenchyme loses

5   syndecan-1 but acquires syndecan-2. In tumors from cell types that lose syndecan-1 upon differentiation but express a different syndecan, utilization of the ectodomain from the syndecan that is expressed in the differentiated state would be indicated.

The examples below are for illustrative purposes only and are not

10   deemed to limit the scope of the invention.

EXAMPLES

The following examples are intended to illustrate, but not to limit the invention.

EXAMPLE 1

15   Deletion mutant syndecan constructs

Using liposome transfection and subsequent selection of stably transfected cells clones by geneticin as described by Leppä et al., *Proc. Natl. Acad. Sci. U.S.A. 89*: 932 (1992), S115 cell line clones (see Fig. 3) were produced that expressed either the wild type mouse syndecan-1

20   (Wild type), a deletion mutant with a single arginine residue in the cytoplasmic domain only (Tail-less) or only the ectodomain of syndecan-1 (Ecto 2; see Fig. 3). These three forms and the hosts were constructed as follows.

The full-length mouse syndecan-1 cDNA, as described in Mali *et*

25   *al., J. Biol. Chem. 268*:24215-24222 (1993) was cloned into the EcoRI site of Bluescript SK+ (Promega).

1) The EcoRI insert of the Bluescript construct was cloned into the EcoRI site of the pBGS vector (Mali *et al., J. Biol. Chem. 268*:24215-24222 (1993)) and the orientation was confirmed. This construct was

30   designated "Wild-type."

-15-

2) A mutagenic 25-base oligonucleotide having the sequence:
5'G CTG TAC CGC TAG CAG AAG AAG GAC-3' [SEQ ID No. 1],
containing a stop codon and a NheI restriction site (underlined) was
used to convert the codon for the second amino acid (methionine) of the

5 cytoplasmic domain following the transmembrane domain to a stop
codon. The mutation was confirmed by restriction digestion and dideoxy
sequencing. The EcoRI insert of the Bluescript construct was cloned into
the EcoRI site of an amplifiable pBGS vector (Mali *et al., J. Biol. Chem.*
268:24215-24222 (1993)). This mutant syndecan-1 containing one

10 amino acid (arginine) in its putative cytoplasmic domain was designated
"Tail-less."

A mutagenic 33-base oligonucleotide
5´-GACACCTCCCAGTACTCACTTCCTGTCCAAAAG-3´ [SEQ ID No. 2]
containing a stop codon (bolded) and a ScaI site (underlined) was used

15 to convert the first codon (E) after the dibasic protease sensitive site of
the ectodomain to a stop codon. The mutation was confirmed by
restriction digestion and dideoxy sequencing. This was the Bluescript-
ecto construct. The EcoRI insert of the Bluescript-ecto construct was
cloned into the EcoRI site of pJC119R vector (Miettinen *et al., J. Cell Sci.*

20 *107*: in press, (1994)). XhoI digested ecto insert from pJC119R-ecto
construct was ligated into XhoI site of pMAMneo eucaryotic transfection
vector, available from Clontech, Palo Alto (Leppä et al., *Proc. Natl. Acad.*
Sci. U.S.A. 89, 932 (1992)), and the orientation was confirmed by
restriction digestions.

25   EXAMPLE 2

Expression of mutant syndecan-1 normalizes malignant growth in S115
cells

Wild type syndecan-1 and cytoplasmic deletion mutant (Tail-less)
were cloned into the EcoRI site of the pBGS eucaryotic expression

30 vector (Mali et al., *J. Biol. Chem. 268*: 24215 (1993), but the ectodomain
construct was cloned into pMAMneo vector, in order to obtain efficient
expression levels also in the presence of hormone (personal
communication, S. Ala-Uoti, Turku Centre for Biotechnology).The pBGS
system is not repressed by testosterone. Syndecan-1 expression at the

35 cell surfaces was detected using mAb 281-2 (Jalkanen et al., *J. Cell Biol.*

-16-

101: 976 (1985)) that recognizes the ectodomain of mouse syndecan-1 core protein, and actin filaments were visualized using rhodamine-conjugated phalloidin.

Cells (S115+, wild type, tail-less and Ecto 2) were cultured four
5   days on coverslips in DMEM-5% FCS-1mM Na-pyruvate with 10 nM testosterone, except S115- cells which were cultured without testosterone in DMEM-4% DCC-FCS (Dextran-Coated-Charcoal treatment eliminates endogenous steroids from serum) with 1mM Na-pyruvate. Cells were fixed with 0.1% Triton-X-100, 2%
10 paraformaldehyde and incubated with rhodamine-conjugated phalloidin (Sigma). Cell surface syndecan-1 expression was visualised by incubating living cells for 1 hour on ice with rat mAb 281-2 (recognizes mouse syndecan-1 ectodomain); they were then fixed with 2% paraformaldehyde and bound mAb 281-2 was visualized using FITC-
15 conjugated rabbit anti-rat IgG.

Without testosterone S115 cells exhibited organized actin filaments typical to these cells when epithelioidal. In the presence of hormone actin was disorganized and globular, and the cell surface expression of syndecan-1 was also suppressed as shown earlier by
20 Leppä et al., *Cell Reg.* 2,1 (1991), Fig. 4.

Wild type and Tail-less clones expressing syndecan-1 at the cell surfaces restored actin filament organization in spite of the testosterone treatment, Fig. 4.

EXAMPLE 3

25 Effect of secreted syndecan-1 ectodomain on cultured S115 cells

Because transfection of the Tail-less mutant induced changes similar to those of the wild type syndecan-1, S115 cells were transfected with the ectodomain. More than 50 independent clones secreting different levels of the ectodomain into the culture medium (see Figure 5,
30 6 and 7) were produced. The cell surfaces of these cells stained only faintly for syndecan-1 but still these cells revealed well organized actin filaments and an epitheloid morphology (Fig. 4). These results

-17-

suggested that ectodomain of syndecan-1 is sufficient enough to restore epithelioid morphology of testosterone treated S115 cells.

To analyze in detail Ecto clones, amounts of secreted syndecan-1 ectodomain from the culture media were measured by enhanced
5   chemiluminescence method using mAb 281-2 against ectodomain of syndecan-1 core protein. Two separate stably transfected cell clones secreting high amounts of syndecan-1 into the culture medium (Ecto 2 and Ecto 23) and two cell clones with low expression (Ecto 15 and Ecto 34) were selected for further analysis (Fig. 5).

10   A clear correlation between syndecan-1 ectodomain expression and re-organization of actin filaments was detected in the presence of 10 nM testosterone: Ecto 15 and Ecto 34 with low syndecan-1 expression had disorganized, mainly globular actin, but Ecto 2 and Ecto 23 clones expressing syndecan-1 ectodomain exhibited epithelioid morphology
15   with organized actin filament bundles (Fig. 6). Enhanced expression of intact syndecan-1 has been shown previously to suppress tumor growth of testosterone-treated S115 cells (Leppä et al, *supra*), and now also Ecto 2 and Ecto 23 clones with high syndecan-1 ectodomain expression restricted their growth in soft-agar. The low syndecan-1 ectodomain
20   expressing clones Ecto 15 and Ecto 34 clones, however, demonstrated soft-agar growth typical to parental S115 cells (Fig. 7). Soft agar experiment indicated that in addition to morphology, syndecan-1 ectodomain expression is sufficient to restrict also the tumorigenic growth of S115 cells.

25   EXAMPLE 4

Isolation and purification of syndecan ectodomain from Ecto cell cultures

Because syndecan-1 ectodomain seemed to be responsible for the suppression of the malignant growth behavior of androgen treated S115 cells, we collected conditioned medium from Ecto cell cultures for
30   ectodomain isolation. Conditioned cell culture medium was denatured with 2M urea and boiling, before loading to DEAE-sephacel column, 50 mM Na-acetate (pH=4.5) was added and medium was chilled to +4°C. The column was washed with 0.2 M NaCl, 2 M urea, 50 mM Na-acetate (pH=4.5), and the bound material was eluted using 1 M NaCl, 2 M urea,

-18-

50 mM Na-acetate (pH=4.5). Fractions containing syndecan-1
ectodomain was dialyzed against phosphate buffered saline (PBS) at
4°C. Amount of syndecan-1 ectodomain in fractions was estimated by
slot-blotting and subsequent enhanced chemiluminescence method
5   using mAb 281-2 (Example 2 and Miettinen, H.M. *et al.*, *J. Cell Sci.* in
press (1994)) and comparing the amount to the known syndecan-1
standard.

Ectodomain of syndecan-1 from cultured medium of Ecto cells
was biochemically similar to the syndecan-1 ectodomain isolated from
10   normal murine mammary epithelial cells (NMuMG). After isolation, the
syndecan-1 content of the preparate was measured and the preparate
tested on hormone-treated S115 cells. As shown in Fig. 8,
concentrations of the DEAE-isolated syndecan-1 ectodomain as low as
1 nM suppressed the growth of testosterone treated S115 cells (Fig. 8).
15   The same concentration only slightly inhibited the growth of NMuMG
cells, which served as normal epithelial cells (Fig. 8). Syndecan-1
ectodomain was also isolated from the culture medium of NMuMG cells,
and also with this preparate, a 1 nM concentration inhibited growth of
hormone-treated S115 cells (Fig. 9). Treatment of the DEAE-isolated
20   ectodomain with heparitinase totally abolished the growth inhibitory
activity of these preparates (Fig. 9), suggesting that the core protein of
syndecan-1 as such was not involved.

The DEAE-isolated syndecan-1 ectodomain was further purified
using a mAb 281-2 immunoaffinity column: DEAE-isolated syndecan-1
25   ectodomain in PBS was loaded onto a mAb 281-2-Sepharose CL-4B
immunoaffinity column as described in Jalkanen et al., *J. Cell Biol. 105*:
3087 (1987), and the bound material was eluted with 50·mM
triethylamine (pH=11.5). Fractions containing syndecan-1 ectodomain
were dialyzed against distilled water and subsequently lyophilized. After
30   that syndecan-1 ectodomain suspended in DMEM (Gibco) and the
amount was estimated, as described above. Again, at 1 nM
concentrations of this immunoaffinity purified syndecan-1 ectodomain,
growth inhibition of testosterone-treated S115 cells was observed and
only a mild effect was evident with NMuMG cells (Fig. 10). On the other
35   hand, heparin sulfate (HS) or chondroitin sulfate (CS)
glycosaminoglycan chains alone did not suppressed S115 cell growth,

-19-

even if used at thousand-fold higher concentrations than syndecan-1 ectodomain (Fig. 11).

EXAMPLE 5

Effect of isolated syndecan-1 ectodomain on cultured cell lines

5   The inhibitory effect of the isolated syndecan-1 ectodomain was also tested on several other cell lines. These included poorly differentiated squamous cell carcinoma cells (CarB), human mammary tumor cells (MCF-7; ATCC HTB 22), S115 cells with (S115+) and without hormone (S115-), NIH 3T3 fibroblasts (ATCC CRL 1658), normal

10   mammary epithelial cells (NMuMG; ATCC CRL 1636), and human keratinocyte cells (HaCaT; Fig. 12).

         Cells were cultured and analyzed as described in Fig. 8 in the following mediums during the indicated periods of time: CarB cells (M. Quintanilla, K. Brown, M. Ramsden, A. Balmain, Nature 322, 78 (1991))

15   were cultured in HAM-F12-10% FCS for four days; MCF-7 cells in DMEM-5% FCS supplemented with 10 nM estradiol (E_2) and 10 µg/ml insulin for 4 days; S115+ and S115- cells were cultured as in Fig. 3 for three days; NIH 3T3 cells in DMEM-5% FCS for 4 days, NMuMG and HaCaT cells in 10% FCS-DMEM for 4 days. Because S115- cells have

20   much slower growth rate than S115+ cells, 3000 S115- cells (other cell lines 1500 cells) were proportionally added to the well, so as to provide comparable results with the S115+ cells. Therefore, for S115- cells, 3000 cell were transferred to the plate as opposed to 1,500 cells for the other samples.

25   Those cell lines which form tumors (CarB, MCF-7, S115+), revealed strong growth suppression when exposed to syndecan-1 ectodomain at a 1 nM concentration (Fig. 12). In constrast, only moderate or no inhibition was observed with rest of the tested cell lines (S115-, NIH 3T3, NMuMG, HaCaT; Fig. 12), which all are all regarded as

30   non-tumorigenic. Hormone exposure doubles the growth rate of S115 cells (Leppä et al., supra) but if syndecan-1 ectodomain is included in the cultures, the growth of S115 cells without androgen was 5.4 times higher than the growth of the same S115 cells with testosterone (Fig.

-20-

12). This was due to inhibition of the "malignant" behaving S115+ cells and undisturbed growth of epitheloid S115- cells.

EXAMPLE 6

Suppression of tumor in vivo-growth by syndecan-1 ectodomain

5   The ecto construct was made as described in earlier examples using the full length mouse syndecan-1 cDNA cloned in the Bluescript SK+ vector (10) and a mutagenic 33-base oligonucleotide 5'-GACACCTCCCAGTACTCACTTCCTGTCCAAAAG-3´ [SEQ ID No.: 2] containing a stop codon (Bold) and a ScaI site

10   (CAGTAC) to convert the first amino acid (E) after the dibasic protease-sensitive site of the ectodomain to a stop codon. The mutation was selected by restriction digestion and confirmed by dideoxy sequencing. Wild type syndecan-1 and the cytoplasmic deletion mutant were cloned into the EcoRI site of the pBGS eukaryotic expression vector (Mali et al.,

15   J. Biol. Chem. (1993) 268, 24215-24222). The ecto mutant was ligated into the XhoI site of the pMAMneo eucaryotic transfection vector (Leppä et al., PNAS (1992) 89, 932-936) because we knew that pMAMneo transfected S115 cells work well in a bioreactory system (personal communication, Sari Ala-Uotila, Turku Centre for Biotechnology). S115

20   cells were transfected using liposome transfection and subsequent selection with Geneticin as described earlier (Leppä et al., PNAS (1992) 89, 932-936).

      S115 cells and transfection cell clones were cultured in DMEM-5% FBS-1 mM Na-pyruvate with 10 nM testosterone, except for S115-

25   cells which were cultured without testosterone in DMEM-4% DCC-FBS (Dextran-Coated-Charcoal treated-fetal bovine serum, eliminates endogenous steroids from serum) with 1mM Na-pyruvate.

      For tumor growth subconfluent cultures were detached with trypsin, washed with DMEM and counted with Coulter Counter (Coulter

30   Electronics). Cells were resuspended in DMEM at a density of 5×10^7/ml and kept on ice until injection. Athymic male nude mice (nu/nu-BALB/cABom) between 6-8 week old (Bomholtgård, Rye, Denmark) were injected subcutaneously with 0.2 ml of the cell suspension. A silastic testosterone capsule was simultaneously implanted. Nude mice

-21-

were observed regularly for tumor development and the size of the tumors was measured at intervals in two perpendicular dimensions. When the animals were sacrificed, the lung and liver was evaluated for the possible appearance of metastases. The tumor sizes were measured

5   on days 6, 11 and 15 after injcetion and are blotted as means of five individual tumors in Figure 13. The ectodomain transfected cells formed only acute inflammatory reaction and did not reveal tumor growth, opposite to wild type cells, which formed rapidly growing tumors. This experiment shows the efficacy of syndecan-1 ectodomain as a tumor

10   suppressive agent *in vivo*.

All references cited herein are fully incorporated herein by reference. Having now fully described the invention, it will be understood by those with skill in the art that the scope may be performed within a wide and equivalent range of conditions, parameters and the like,

15   without affecting the spirit or scope of the invention or any embodiment thereof.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

    (i) APPLICANT:

        (A) NAME: Jalkanen, Markku
        (B) STREET: Rauvolantie
        (C) CITY: PIISPANRISTI
        (E) COUNTRY: FINLAND
        (F) POSTAL CODE (ZIP): FIN-20760

        (A) NAME: Mali, Markku
        (B) STREET: Inkereentie 176
        (C) CITY: SALO
        (E) COUNTRY: FINLAND
        (F) POSTAL CODE (ZIP): FIN-24280

    (ii) TITLE OF INVENTION: SUPPRESSION OF TUMOR CELL GROWTH BY
                             SYNDECAN-1 ECTODOMAIN

    (iii) NUMBER OF SEQUENCES: 2

    (iv) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

    (v) CURRENT APPLICATION DATA:
        APPLICATION NUMBER: WO TO BE ASSIGNED
    (vi) PRIOR APPLICATION DATA:
        (A) APPLICATION NUMBER: US 08/258862
        (B) FILING DATE: 13-JUN-1994

(2) INFORMATION FOR SEQ ID NO: 1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 25 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: both
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (genomic)

    (iii) HYPOTHETICAL: NO

    (iii) ANTI-SENSE: NO

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

        GCTGTACCGC TAGCAGAAGA AGGAC

(2) INFORMATION FOR SEQ ID NO: 2:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 33 base pairs
        (B) TYPE: NUCLEIC ACID

        (C) STRANDEDNESS: both
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: DNA (genomic)

   (iii) HYPOTHETICAL: NO

   (iii) ANTI-SENSE: NO

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

         GACACCTCCC AGTACTCACT TCCTGTCCAA AAG

-24-

WHAT IS CLAIMED IS:

1. A method of decreasing the growth of a tumor cell wherein said method comprises providing efficacious levels of syndecan ectodomain to the extracellular environment of said cell.

5

2. The method of claim 1, wherein said cell is selected from the group consisting of epithelial cells, mesenchymal cells, pre-B cells and plasma cells.

10   3. The method of claim 2, wherein said cell is selected from the group consisting of a breast cell, an endometrium cell and a prostate cell.

4. The method of claim 3, wherein said cell is steroid-responsive.

15

5. The method of claim 4, wherein said steroid is estrogen or androgen.

6. The method of claim 1, wherein said cell is a human cell.

20

7. The method of claim 6, wherein said syndecan ectodomain is that of the human syndecan-1 of Figure 1.

8. The method of claim 7, wherein said ectodomain comprises
25   amino acids 18-231 of figure 1 but not the transmembrane or cytoplasmic domain as shown in amino acids 252-310 of Figure 1.

9. The method of claim 8, wherein said ectodomain comprises amino acids 18-251 of Figure 1.

30

10.   A method for treating a patient in need of treatment to reduce or suppress the growth of a tumor in said patient, wherein said method comprises administering to said patient, a composition that comprises efficacious levels of syndecan ectodomain to the extracellular

35   environment of said cell.

-25-

11.   The method of claim 10, wherein said cell is selected from
the group consisting of epithelial cells, mesenchymal cells, pre-B cells
and plasma cells.

12.   The method of claim 11, wherein said cell is selected from
the group consisting of a breast cell, an endometrium cell and a prostate
cell.

13.   The method of claim 12, wherein said cell is steroid-
responsive.

14.   The method of claim 13, wherein said steroid is estrogen or
androgen.

15.   The method of claim 10, wherein said cell is a human cell.

16.   The method of claim 15, wherein said syndecan
ectodomain is that of the human syndecan of Figure 1.

17.   The method of claim 16, wherein said ectodomain
comprises amino acids 18-231 of Figure 1 but not the transmembrane or
cytoplasmic domain as shown in amino acids 252-310 of Figure 1.

18.   The method of claim 17, wherein said ectodomain
comprises amino acids 18-251 of Figure 1.

19.   A pharmaceutically acceptable composition for
administration to a patient, said composition comprising a protein having
a domain consisting of the syndecan ectodomain.

20.   The pharmaceutically acceptable composition of claim 19,
wherein said syndecan is human and having the sequence shown in
Figure 1.

21.   The pharmaceutically acceptable composition of claim 20,
wherein said ectodomain comprises amino acids 18-231 of Figure 1 but

-26-

not the transmembrane or cytoplasmic domain as shown in amino acids
252-310 of Figure 1.

22.   The pharmaceutically acceptable composition of claim 20,
5   wherein said ectodomain comprises amino acids 18-251 of Figure 1.

```
1      ggagaggtgcgggccgaatccgagccgagcgagaggaatccggcagtagagagcggactc
       cagccggcggaccctgcagccctcgcctgggacagcggcgcgctgggcaggcgcccaaga
       gagcatcgagcagcggaacccgcgaagccggcccgcagccgcgacccgcgcagcctgccg
       ctctcccgccgccggtccgggcagcatgaggcgcgcggcgctctggctctggctgtgcgc
                                     M  R  R  A  A  L  W  L  W  L  C  A    12
       gctggcgctgagcctgcagctggccctgccgcaaattgtggctactaattgccccctga
       L  A  L  S  L  Q  L  A  L  P  Q  I  V  A  T  N  L  P  P  E      32
301    agatcaagatggctctggggatgactctgacaacttctccggctcaggtgcaggtgcttt
       D  Q  D  G  Ⓢ  G  D  D  S  D  N  F  Ⓢ  G  Ⓢ  G  A  G  A  L    52
       gcaagatatcaccttgtcacagcagacccccttccacttggaaggacacgcagctcctgac
       Q  D  I  T  L  S  Q  Q  T  P  S  T  W  K  D  T  Q  L  L  T     72
       ggctattcccacgtctccagaacccaccggcctggaggctacagctgcctccacctccac
       A  I  P  T  S  P  E  P  T  G  L  E  A  T  A  A  S  T  S  T     92
       cctgccggctggagagggggcccaaggagggagaggctgtagtcctgccagaagtggagcc
       L  P  A  G  E  G  P  K  E  G  E  A  V  V  L  P  E  V  E  P     112
       tggcctcaccgcccgggagcaggaggccacccccgacccagggagaccacacagctccc
       G  L  T  A  R  E  Q  E  A  T  P  R  P  R  E  T  T  Q  L  P     132
601    gaccactcatcaggcctcaacgaccacagccaccacggcccaggagcccgccacctccca
       T  T  H  Q  A  S  T  T  T  A  T  T  A  Q  E  P  A  T  S  H     152
       cccccacagggacatgcagcctggccaccatgagacctcaacccctgcaggacccagcca
       P  H  R  D  M  Q  P  G  H  H  E  T  S  T  P  A  G  P  S  Q     172
       agctgacctttcacactcccacacagaggatggaggtccttctgccaccgagagggctgc
       A  D  L  H  T  P  H  T  E  D  G  G  P  S  A  T  E  R  A  A     192
       tgaggatggagcctccagtcagctcccagcagcagagggctctggggagcaggacttcac
       E  D  G  A  S  S  Q  L  P  A  A  E  G  Ⓢ  G  E  Q  D  F  T     212
       ctttgaaacctcggggggagaatacggctgtagtggccgtggagcctgaccgccggaacca
       F  E  T  Ⓢ  G  E  N  T  A  V  V  A  V  E  P  D  R  R  N  Q     232
901    gtccccagtggatcaggggggccacgggggcctcacagggcctcctggacaggaaagaggt
       S  P  V  D  Q  G  A  T  G  A  S  Q  G  L  L  D  R  K  E  V     252
       gctgggaggggtcattgccggaggcctcgtggggctcatctttgctgtgtgcctggtgggg
       L  G  G  V  I  A  G  G  L  V  G  L  I  F  A  V  C  L  V  G     272
       tttcatgctgtaccgcatgaagaagaaggacgaaggcagctactccttggaggagccgaa
       F  M  L  Y  R  M  K  K  K  D  E  G  S  Y  S  L  E  E  P  K     292
       acaagccaacggcgggggcctaccagaagcccaccaaacaggaggaattctatgcctgacg
       Q  A  N  G  G  A  Y  Q  K  P  T  K  Q  E  E  F  Y  A  *        310
       cgggagccatgcgccccctccgccctgccactcactaggcccccacttgcctcttccttg
1201   aagaactgcaggccctggcctcccctgccaccaggccacctcccagcattccagcccct
       ctggtcgctcctgcccacggagtcgtgggtgtgctgggagctccactctgcttctctgac
       ttctgcctggagacttagggcaccagggttttctcgcataggacctttccaccacagcca
       gcacctggcatcgcaccattctgactcggtttctccaaactgaagcagcctctcccagg
       tccagctctggaggggaggggggatccgactgctttggacctaaatggcctcatgtggctg
1501   gaagatctgcgggtgggggcttggggctcacacacctgtagcacttactggtaggaccaag
       catcttgggggggtggccggctgagtggcaggggacaggagtcactttgtttcgtggggagg
       tctaatctagatatcgacttgtttttgcacatgtttcctctagttctttgttcatagccc
       agtagaccttgttacttctgaggtaagttaagtaagttgattcggtatccccccatcttg
       cttccctaatctatggtcgggagacagcatcagggttaagaagactttttttttttttttt
1801   ttaaactaggagaaccaaatctggaagccaaaatgtaggcttagtttgtgtgtgttgtctct
       tgagtttgtcgctcatgtgtgcaacagggtatggactatctgtctggtggccccgtttct
       ggtggtctgttggcaggctggccagtccaggctgccgtggggccgccgcctctttcaagc
       agtcgtgcctgtgtccatgcgctcagggccatgctgaggcctgggccgctgccacgttgg
       agaagcccgtgtgagaagtgaatgctgggactcaggccttcagacagagaggactgtaggg
2101   agggcggcaggggcctggagatcctcctgcagaccacnccgtcctgcctgtgcgccgtc
       tccaggggctgcttcctcctggaaattgacgaggggtgtcttgggcagagctggctctga
       gcgcctccatccaaggccaggttctccgttagctcctgtggccccaccctgggccctggg
       ctggaatcaggaatattttccaaagagtgatagtcttttgcttttggcaaaactctactt
       aatccaatgggttttttccctgtacagtagattttccaaatgtaataaactttaatataaa
2401   gtaaaaaaaaaaaaaaaaaaaaaaaaaaaa
```

FIGURE 1

```
-4138
-4078 gtcttccctctgtcttctga                tctagatattcaaactcac cagatggagtgatgtccacc cctattggtgggagtgacta
-3998 gctctcttagtacctttaac ccagtggagttgacatgaga aattaactaccataatttat aatatttcatttcataaatg
-3918 aaaagtaaaataaattaaaa aatagaaaggtttgagcatg atggcccagtggtaaaggcc agtggctccaacgcaagtcc
-3838 tgacaaatggtaacgggcct gttcttcaggcttgagggaa gtttattgattgaggctaaa agcaacccaaaggctccact
-3758 tgcctagtgtgaagccctgg atgtgctctcccacactgca tgtccacctgtggtgtcagc acctgggaagctgaggatga
-3678 tggggagtccaaggtcatta gctacatagtatataggctagc tggggtacatgggtcacaaa aagaaaaaaaaataagcac
-3598 attgtaatcccagcacttga cagaccaatgggggggggat tgctgtgagtttaagacagc ctggcctacaaagaaaaacc
-3518 ctacccaaacccaagaaaaa tgaaaccagtaatataaata gctattttcattttaaatgc tctaaagacacagcgttaac
-3438 acaaaagctctcgtctgtgg ttcctattccctccttctcc cccaggtcttctttaatgta tacttttttgtttgcttattt
-3358 gcttgttttggattttggct tttaaagacagggtctcact atgtagctccaactatttgg gaactcactatgtagaccag
-3278 gctagccagggacttataga gatctacctaccactgcctc ccaagtgctgagactaaagg catgtgacactttgcttggt
-3198 tattacaaacatttttaaaag aacatttgaacattaatag atgtatgtatatatatcact ctatgtagtatatatgttag
-3118 acatttttcacttgagatac atatttactctcaaaataag tttttttgtttttttttttcttc ttttttaaatttatttttttt
-3038 ttttttttatttattttatta ttatatgtaagtacactgta gctgtcttcagacanaccag aagagggagtcagatcttgt
-2958 tacggatggttgtgagcacc atgtggttgctgggattcga actctggaccttccgaagag cagtcgggtgctcttaccca
-2878 ctgagctatctccaccagccc cttaaatttattttttatctt atgtccattggtgttttgcc tgcatgtatgtgtaaaagtg
-2798 tcagaaactgaagttacaga ctgttgtgagctaccattgt tgtgggtgctgggacttgaa cctgggtcctctggaagagc
-2718 agtcattattcttaaccact gagccatctctctagccctc gttttttagttttttttttt gttttgtttttgtttttttgtt
-2638 ttttaagatttttcttattt attatatgtaagtacactgt agctgtcttcagacactcca gaagagggcgccagatctcg
-2558 ttatggatggttgtgagcac catgtggttgctgggaattg aactccagacctttggaaga gcagtcagtgctcttaactg
-2478 ctgagccatctctccagccc cgttttttaggttttttgaag acagggtttcctgtgtagct ctagctgtccaggaactagc
-2398 tctgtagaccaggttggcct caaatttagagatttgcctg tctctctgcctctcgagage tgggattaaaagtgtgcagc
-2318 ccaacaatctactcaaagta ggttttgaaaaagctttcca tattaggagttaactagctt cattaaaaatactgcatg
-2238 gaattcaaatgtgggaccat tcatagctactttggtttto cttcagtgacaggcattcgg catgctattaggaagtca
-2158 aatggcctggagaagtcatc ctgggtgagaggctaatgc attttcagcttgacagacac tgtcaacctatgcagacagt
-2078 ctgctccagctcagatgtca attgcatgcagacctgcagt cagacgctaagctccctace tactctccatcagcttagat
-1998 gtaaggggtgctggaacaaa ggctctctctctctctct ctctctctctctctctct ttcttagaattagtattcta
-1918 ttttatttttatgtaaattgg tacttcacttacatgtatgt ccgtgtgaggatgttgtatc ctctggtactggagttatag
-1838 acagctgtaagtcgccatac aggtgctgggaattgaaccc tgatcctctggaagaatagt cagtgctcttaacccctgag
-1758 ccatctctccaacctcttgc atattgaggacagggaggaa tcacaagccatgtagggtgc ctgggctctgaggtcaacag
-1678 gaccatagcctcctttcttt atgtgcctttcttgggggtct ccctataggagtcgtcttcg ttgcctctttactgtctcat
-1598 tgatctgggctaaacttatg cagttggaaggaaagatcaa gctggtcatgtttaaaacat gaaacagcctcatcagttcc
-1518 cttcctgttcccgtctcccc ccccctcccgccccatt tgagagacaggaaggtaaa ataccaaagtgtcctatttt
-1438 cctccaaatatcaggctcaa aggactgaagagctgacttc agatcccaaagccactgtgt taggaggcacctgcttttta
-1358 ggtcctaagccttcctgagc cttgctattgggtattcttt accaagaccctcaaggatct aggcaagaactgggcaggat
-1278 ctgtatgtagcccatagtta gacctagggcagctgagacg ccaaaagggagagtttcctg aggacaaaagtgttcaaaca
-1198 caactgggtgctggttgttg ggctactcgtggaggtgtgg tgtgtgtaaaggaggctgtt gaattcccagaaggctggtt
-1118 ccacagtgtagagtctacac tggggacttccgagacgct gagcctcagatctagcttct cagtccaggccagctgatgt
-1038 ggggctgaggaacaaggatg gatgccatctatggccctgc cttgcaggtgcaaagggcct ttggcaccatctacagattg
 -958 agggcaagacagggctggtt cttcctccttgctctcgctg ctatctgctcgcctgtagg ctctctgggctcctttttgg
 -878 actgacacgtctgaaggagc ttggaaactgtgaggtccag gccccatagagaatcatgaa ggaacaggaattcaactgga
 -798 gctccgcagctggttaggcc tgcggtcacctggaaacaaa gaggccattattttttcct ttggtcttggacaaggaaga
 -718 gaaggggctttctataaata gaaagacagcaaaaaagaaa ataataataataataat aataataataataataaaaa
 -638 caataacaaagccagctctt ccagacagtgctcatgtctt taaaggtctttaaaggtctg gagttcccagcaattaagta
 -558 aaggaccaagacctcagggg tccctatcctcagcccgtg gggaggtgggaaccatacat cgatccctcggtttatatat
 -478 agcctcatcgctgtggggct ccgaggttgccccaaaatc ttgctcacctggaggaccc tgggtgtcctcgcccagagg
 -398 gcgctgcagcctcgcacgta gagaactaacatcgcccttc tccagggcagtgcctccgga ctccggaccaggacatagta
 -318 gcgagtgcacctgggtctcc gtcagctacgcatcaaggaa ggtgcgacgcgggaattaca gattgccggcactcaccagt
 -238 gctcaggggaggaaggtggg actcagacctgcaagagctg aagagtgggtgggcttcga tcctaggaggcgtggaaggg
 -158 ggtgtggctggatccctggg gggtggggcgctccaaggg cggggcaacccaggggggcgg ggcccgaggggtggagattg
    3 CTCCGCGGGAGAGGTGCGGG CCAGAGGAGACAGAGCCTAA CGCAGAGGAAGGGACCTGGC AGTCGGGAGCTGACTCCAGC
   83 CGGCGAAACCTACAGCCCTC GCTCGAGAGAGCAGCGAGCT GGGCAGGAGCCTGGGACAGC AAAGCGCAGAGCAATCAGCA
  163 GAGCCGGCCCGGAGCTCCGT GCAACCGGCAACTCGGATCC ACGAAGCCCACCGAGCTCCC GCCGCCGGTCTGGGCAGCAT
```

                                                                                            Me

Figure 2 *(Sheet 1 of 6)*

```
243  GAGACGCGCGGCGCTCTGGC  TCTGGCTCTGCGCGCTGGCG  CTGCGCCTGCAGCCTGCCCT  CCCCgtgagtgtggcccggg
     tArgArgAlaAlaLeuTrpL  euTrpLeuCysAlaLeuAla  LeuArgLeuGlnProAlaLe  uPro

323  gcagggctgggaggcggcgg  gaagccgggactcgccactc  gccgatgccatgcaggcggc  agcacgtggaggggagggg
403  agcgggggacttcttcccgcg  ctgcctggcggatcctggga  tggtgagccctttaatgagg  actcctgtcccaattcctct
483  acggtccgtggatgccagga  ggctatcccagctcgtggtc  cgggcgtcctgcagagtgga  acctccattggttccccgct
563  cccaattaagtaaaacgact  ccacaggggtctgagtcgcc  ggccttaggcgctccgccgg  ccttaggcgccgcttggagt
643  tgctctctcccgttgctgtc  ttgctggccatctcagccgg  ctggcctccgccagtgtccc  ggaggatgcagtggccatgg
723  ccaaacgccttttccataga  ccctaattcaaaccagactg  caggcggcacccccagcgcc  gcggagtccgggcgctcggc
803  cctttgcaccggggcaagtt  tgggcacagcagagccggcg  cgggaacaggggaagctga  cgttcggggtggcgggaggg
883  acgggattaaggctgtttgt  gggacacaagagggtggctc  agggacttcggtttttctct  ggctgccccaggtgagccgg
963  gccgagctggcagcgggagg  ttccgggaagttggcttcag  aacgctgaagaccctaagaa  cccaacttgggtcgctga
1043 agttgtgctgccccggagg   gcctcctccgcatggcccgc  gcgggggaccctccccgcga  gtggaccccggtacggctct
1123 tcccctcccccgactcggct  ttgtgctgaagccgcgcgta  gggaaggcgggtccttggc   ccgcccagtaggcgcggg
1203 gaaagagggacgaacgtgga  gctggcgactggtgggggaa  gcttctgggtaggatgcagc  catccacctttggtggggtc
1283 ggtctctctaatcagcggct  tggcgacaaagagcttggtc  gagggtaccccagaaagtgc  tctcccgcccaagccgcg
1363 tcgctagcccgccttcccaa  cgggcgctttgttctcggcc  cctgtaacccttccctggga  accgcccgcagcgctggtc
1443 cttgacgtgggccgggtcct  gggtcgccgccagtgtcagc  gctgccctccggtgtccacg  ccctagccccgcacccgc
1523 tgtgaagtcccgggtgtcct  ttccactggcgctttgccca  accctggaaggcagaggcg  aggtgcggagcctcaggctt
1603 tatcctcccggaagtggcag  tctccaccgccacatctgg   tctgcttaacttcgatagtc  ctggcaaaggcagacacgtg
1683 cacagggaaggagagttgag  cgctggtagataccaaggtc  gtgtacaaataaagtggcac  acgacacgtccccagtcact
1763 gttaatgcattgccttcgct  ccttcccaggtggctggtgc  tctccatcactctggagccc  aagagagggcctccataatt
1843 gtattgcccatgagttgggg  ttgtgtgggggcgccaaatc  agggttctctgggagggcta  tgaattccgaactgagtctc
1923 ctgtgcactcctggctttaa  ggttcaagaaattgtttgag  ggttgtgtggtttttgtggga c  tcagattatgcctggaatca
2003 tagttaccactgtggagaag  aaagtggagctacttagcat  gcctccccgccccgcctggc  attacctccggctctgttct
2083 ctaggcccaacgtgaggcct  cactgggcagtacagatgc   agtactgaatttcttttccag  ccaggatctggagaggtggt
2163 gttctcttccctggtgtctt  tagagaggcagatattcctg  tgacctaagcccctcaagca  cccattaataatgctgagta
2243 gacaactagaggtggcgttt  tccggaacttcctgtgtgct  ggcctgggaggttgaaccct  ctaggaaacaggtctaggaa
2323 gtagaattatctcaatggaa  ggcttcctggaggaagaaga  tgagctgagcccccaggtca  ctgtctgagctttagatca
2403 gactcccacttggaggcaag  agtgttcgtttttactttttt  tttttaagtttagtttattt  tctctctaacagaaaacaaa
2483 caaacaaacaaaaaaaaacc  ccacattgtttaaaagtggg  tgcataagagtgaggacata  ttcagagcttcccctttttcc
2563 tgaaaatgaaggcagctgg   gatttacttaaaatgagagc  acatatcacaattgccagag  agctggtccctttctcaggg
2643 ctccctaagctcctgtggga  agcaggtcagacagccctgg  ggaccagagagatagggagt  gcttttgggtgcctgccttt
2723 gaatggggaagggggggggga  gctgctgggatcagaggctg  ctagcaactactcccagag   actgaagcaggtttgtccct
2803 cagtgtcctgtggtcttctg  ttttctcctatatagaataggg  agaaatggttatttgctctg  gaatagtgacttgctatttg
2883 ttcccttttcttttcctctccc  ttactgtaatcatttggact  agtagacacttttcccag    gtctggcagaatgggaggga
2963 gtgggggaggcctgtgcttg  catgatgtcactgctggctt  cagctctccagggggaggtgg  agttggttgtaacctacctg
3043 tggctcttgatgggccacaa  taaaacctcattaacacaca  ttggtagggagaaggactg  gaaagaatgatgggaaagat
3123 tgatgtttttccttttttttt  ttttttttttttttggcagta  cttctagatctcccctcca  ccttgctgcagcaaaatttt
3203 ggattcctgaagtcctttga  gaatgtataatggtagccag  acttttttttttttcagtcag  ctcaaaattgcctccttata
3283 aagtatccttggttgtttttt  tgttgttgttgttgttgttg  ttttgtttttgtttttaagaca  aggtttctctgtatagtcct
3363 ggctgccctggaactcaata  tgtagaccaggctggcctca  aactcaaagaaatccaccta  cttctaactttcagtgctgg
3443 gcctaaaggtgtaggccacc  aaaagtgctcaactttttaca  aagcagtcttactttgagca  ggattctgaaaccccttattt
3523 cctttctgttatcttcaaca  atacactgctaggtgtattt  agtccctcatgatgctgggc  ctccctcaagtggcgccaggt
3603 caagcagtctcctggtttttt  ggtggctctgaagaagactg  tgtcccagtgactggcagtt  tgaattcggagcttctcttt
3683 tccttctcagtctttggcag  gcagagtgacactggtgtgc  ccaagcctggagcttctctg  tttaattctagtttatttttc
3763 tttatcagactgaaaaacaa  atcaggttggttataattct  tataaacacgaaggtctcac  cttttcgtacgtctccggct
3843 gtgtgggtctgatgtccctc  gggaatctctgttgaggctg  ctgcagtgtgtgtgcgtgta  gaaagggcaaggtagaatgg
3923 acagaagcgtgctgcccacc  ccactgtcctgttcctaaat  gatgaagcactggcccggtg  aagagcctagagaactccct
4003 cggtgggagatgcacacaat  gccaggaagcacacaggagc  ttgagttccagcttggcagt  gtcttctctttggtgactttt
4083 atcagctccagctgccctgg  actaacaaacaaggctagct  cactctcagtattgataatc  gaaggtccttggttctgtttt
4163 gagactgatcctcactcggt  agccttgaactcttagcaat  tctcctgtctcaactttcaa  agagctgaaattacagactc
4243 gagccaccatatgcgactga  aaccttgttcctaatccttg  actgtgaacgactcttgggt  ttggttctttctccatttct
4323 ttagtgtatgtttttagttcg  cgtcctacataatctattgc  ccatacttagaaacaacagg  ttagagacagcattgggtcc
4403 agcagagcctcacactgaag  ctcagtcctgccactgattt  accgtgtcagctcaagtgac  tcacttccaactcctctgct
4483 ccccatctgtagagtagaca  tcaccataccctgctctttct  gcccacattctgtcattaac  atgttcatttcataacgatg
4563 gtgcaaaagtgctttgtaag  taaagtgctggggaaatgtt  agctgtcgataatggttagg  gttaacttttttattgagtgc
4643 ctgttgtgtgtggggttggg  tggggttttttttagaggctt  ggtagttttcttacttcttt  cctacttagcttttcttcct
4723 aagcctttatggtatgtatc  attgcctgattgtttgagtg  tgtgcactgaggcacgcctg  tgcatgtttgagagtatgct
4803 tgtgcgtgctctcgtgctca  catatgtatggtgtgaatac  actgtagagtgcaggccggc  tgtgtgagtgactgtttagc
4883 ctgtgagccctgcctggagt  ttgcagatcttccttggaca  ctcctgcttgtgagcatttt  gtgtggagtgactgtttagc
4963 tggctgtagcctacattgtg  cctttgggtaaaccctgagt  attgggaaacaccctgggct  gtggctgtgtgtgcccgacg
5043 gttgcttgggtacagctaag  aactcttcatagaaagttga  gctcacatgctattagtatt  aactgagtgctaaggaacct
5123 gtcttgggtggtacctgctt  gccctctcatgcagtttatc  ttgagcttggcgaacacact  tacagatttagtagagcttt
5203 tgtcagccctgggaggtggg  tttcgtggccacaagtgggt  agcttggaatccaagactcc  tggcttctaggttgcattct
```

Figure 2 *Cont. (Sheet 2 of 6)*

```
 5283 cctgtggttcttttccaaggg  aatgctaggggaacactttg  gacattagattatttctagt  cccaaagcacacagaacata
 5363 ctgtttcctaattgcctttt   ttttgttttcctctcaatct  ggttttgaagtgttgggttt  gaaaattgcccctgagagc
 5443 ctgccctagtgtgtgcagag   ggaagatagtggaacaggaa  gtctgtagaaagtatcttcc  tttccaggaccttgtgccc
 5523 ggagcagagtcagcatggtg   tcatatcgcttttggctatt  ccagaagagatgaggtttta  ggtgagaatgaacctttag
 5603 aaccttctagaaccttctgt   tgagtatgacaggaatgccc  tgaatagggtccgaagtgca  tggccacttgtttgtctttt
 5683 ccataagcaagcagcttcag   gtacagacaataagactagg  ttcttggagtgagaccctgc  acttggtgccatttcagctc
 5763 cagatggacactggaggtcc   ctacacagcaggctctggga  tggctggctttgctatgtac  tgttgcctgctctacaagag
 5843 cttcccaggttactagcctt   tgtcgacgctgggctcgctg  gccaggcttgggcattggag  aagggacaacttgccacctg
 5923 gcataggctgtgtgtttgga   gagtcaggaggtctggtgaa  gcccgcaagtggaggcaagt  ttagtgggacttgaggagag
 6003 ctcagtaggaaatctctggg   ctagtgacaggcaggtgtgg  tggtggtggcgaggtggcgg  gtctagatctccttttagag
 6083 atttgcctagggatcgtccc   tgctgactctggaactcaga  ggcctccagaggtgtctcct  ctgggagcctctcaagggtc
 6163 tcccatctcctactgtttat   ggctttgtgggctacctaat  tacatagagaagatatgttc  ctctgcctccagccctggaa
 6243 agttctgcccagtgactcac   ctgagcctgcagccatgtgt  gtacacaggcgctctcaggg  gcttctgtcctgctggcttc
 6323 agcctttctagccctggtg    ttctcggcagtggtagcatc  tgggaaacgggtcacctct   tatttgcagctcctccctt
 6403 tcttggtgtcttcccccttt   ttaactactggtctgatggc  cttagactcatgtcgaaatt  ctcctttcttttgtcctagc
 6483 cttgtctctgacttcttgtg   atcctctgggcctgtgaaat  ccgctcagggcctccattt   ctaacagtcacacactggtg
 6563 gagagaccgagtcctgggat   ggtgaagctaaccctgctgg  gcttctcaagcttcatttgg  ttctctttattccttctgg
 6643 aggtactgcctgcccaggg    gagtctcagactagaccact  ctggagttggaggtggggca  ggttttcagatcagtgccct
 6723 tggcattcgttgtgggaatg   gggtggatggggcctctggg  caaggtcaggctgggggtgg  aggccaggtgatgttctccg
 6803 cacccacacccaggcagcct   ggcaccctccccaaggtccg  ctcatcagcaggaatgaaag  cagtgccgggcaggtggggg
 6883 cagtgggcaggtgggcgtgt   ttatcgctgtgctcatcagc  tgagtcacgatgccaggccc  cacaagtcctccctggaggc
 6963 tcacccacccacttgacc     caccagcacccactagcagg  aggtagggcagggcagtgag  acaagaccagcctgggggtc
 7043 tgagaggcaaaggggagttg   ttcatgacctggctgtgcat  ggggacttgtgggtgtctca  gatatctctgctgtccagga
 7123 ggaagctgtcttaagtgcca   acctgcctagagccctgct   gggtgcaggaaatgcacaag  ggagagtgcccatccatgga
 7203 ataggcccatggagctagac   cagtgacagtgacagtgaag  tcagcccccacctgtgtctt  ccgagccagctggagggttt
 7283 ttatctcagattctgcgaaa   ccatagaatctagtcagtgag cctagactgcaaagcaggct  tcgttgatgctttaacttgc
 7363 aggcttcctgggtatgaggg   atacttagaaaggtcccgca  ggtagggagggcatcaggaa  gtagaagagggccaggcact
 7443 tctatctcctgcattgcccc   cttctcccatctccaaggat  ggtaaaaagaacccttccag  tacactgacagagaggaaaa
 7523 cccttcatctcaccccattt   ggatctgtcgtatcagcatg  tgctggccctgcttccatac  cagaggtggctagagatgtt
 7603 ccctgggaattcactggttg   gggacttgagtgtatcagag  gggcacaaagtaacattaac  tctggtatcctctgcagcaa
 7683 atcggagatcccctctccta   ggcgagttctcagtggatat  ggaggtcaggtttgggcttg  tagggcccagcaagagtcg
 7763 ttgatgtcactccagcttct   cccgaggaagatgagggtgc  tgtgttgggatcacatctct  ccctgaatggcatgttgggg
 7843 agggatggagcccttgcttc   tgaccctaagcttggtctt   taggtggccacagtctctgg  gttctgtcctacctccctgc
 7923 ccttgtgtgcttcaaaaggca  tgctaaagggactctcggcc  attccgaatggcacagtgtt  cttctgttctcccacccc
 8003 agaaggaggcaggcctggat   tgtagattcctagaagtaag  tggccctgagcatgctgttg  atgaacctggaaccaggcag
 8083 gctgggcatcctaggacctg   tctttccatagaagtctgaa  tcagtctaccttgggactg   agtaaggggctcctcacata
 8163 tcagctggctagtccatctt   ggctgatctaaaccacatta  ggctgaagagaagcatggtg  tacagtctggtccacccgaa
 8243 ccacatactggctttatcag   ttctcgtataatttttgcagt taactttttagctctaagcc  tgtctcctcatctgtgaaat
 8323 cgggtccctcatatcctgcc   tagaagggcttttgaaaaga  ttaatgaagtagtatgccga  gtggttggggttctctcctt
 8403 gactggagcaagtctctagg   agtactaaggatagcctgct  gtgtgcagcaccccaggga   ctgtgcctgagtaggagggt
 8483 acagagtcttcatgtgaatg   gcccttctggtcttgccccg  aagttagtgttgatgtcata  gagtctacaaacatgcctt
 8563 tgtccttcctcagaagtcca   agcctttcctggcagaccag  acattcatctccactgagcc  tctatgtgagactggctcct
 8643 ggcctgagctgtgtgggctg   agctggcgaatgggaaaact  agacacctgggcacctggt   ggggggctcgggacagcagtg
 8723 tttcagttgtaggcactgtg   ccctgcctggagcttctga  ctgaaggttaccctgagagg  aagcaggtccctatagaca
 8803 ctaacatagctgggtcagag   tgcaaggtgggtgtgccct   gccctgacccattcagtgca  aaggctgctcttctgggagt
 8883 gagagctctgacaggactgt   gatggccgaggggtctcaga  gcaaacctgcctggcctctc  cccactctgatggatatgtg
 8963 ctcttaaacaagtgactgtc   cacttttgcctcaatttcaac atctgtaagatagatagggc  gttatggtctgaaaatggtt
 9043 ttaaagattagttagctaat   acaggggaaagtgctctgaca ggtacctggcaccttactca  acaagtggctggagtgcctg
 9123 atttcctaaggtctcgacct   gtccctatgcttcaagttgcc cctacagccttggtcaggcc  cttaggttctcccacccacc
 9203 gctggccccaggacctagac   tgctggaccctgaccccatt  tttcctttaagcacctctg   cgtcaactctaaaaggcggt
 9283 ggagttgtttatctaggctg   tgaggtgtcagagaaaggac  ctggccgcttgttcctgt    gtgggctgggggcactccag
 9363 gaactgagaaacccacccac   cttttcaaaaacagcctctt  ctcagagtctgcaccteag   ctagcaccatgctgtggga
 9443 ccactcccagcatgctctgc   ctttggttgtttcccaggg   gcctcagtgccttttaaaga  tgcacaggcatctttagttc
 9523 aagggaaagaggaaatgaa    gtgtatttgctggtggtggt  attcctgtcacttgcattct  cacagaggctaaagaaattt
 9603 gctctttgtatcttctagtc   tcttctttatgatctttcc  catctgttgtatcccaactg  cagggcccagttctagaat
 9683 tagccctcctacaataggaa   gccgacttatgctataatgt  gaatgacaagtatcctttag  cccttcccacaggcatttta
 9763 attttcaaaagggcatttgca  caaccgcagagacactaaga  agagaggttggtgatcaga   gttacagcccagcctccca
 9843 gctggtggcccggctggtgc   aggtgtgtcgaaagcagtag  tttctgcttcagtgaaactt  gaggatcctttatttagcca
 9923 gttcaggggcggaatggcca   tgcgaagtctatgtgtcaca  ggtgtcaggcccccatatcc  tgctgagtctagaatcagct
10003 acgtagcagtttgggggta    ttgccagactgggagtttac  atcccagaagcgagaatggt  ggggttcctatactgctcca
10083 gacaggatctttcccccaag   tttgtcagccacctctcttc  aagtcccttggctctgacca  gcaagacgtatccaaaagaa
10163 actgaggaggccttcactt    cttttaggatagtgtgggg  ccagcatgtgggggttggg   aatggctttctgtctcttcc
10243 atcatcacaggctacttccc   agagacactttgattctggg  catctccagcagtcacctgg  cccacaatgctttgctgccc
10323 tttgcttcagccactgtatc   tggttgtcccttgaaggtga  gccagagctcctaggcagag  agcatgtgctatacaaagcc
10403 gtaggctgggccctgggaac   cttcttgctgtcatcctcct  gtcaaaccccatggtatgg   tagcccacataaggcttgtg
```

Figure 2 (cont) Sheet 3 of 6

```
10483 caaaaaacaggccaaaacat aagttatcttttcactctat cgggtcttcctcattttccca tggtacgttcggctggccag
10563 gcccaaaagattttgaagaga ggtggctggcaagtctaggg gaataggtctatctggttcc ctccaggagcagtgcctagt
10643 gagaggctgggctgggcagg gcagggcccccttgctccaca ttgcctgaagtcccgccctg cccgtcctggctgggatctg
10723 gcaggtcttccagctccaca cccggctccagctgagcct gctcagagactagtcctggc atgtgggttgcagggctggt
10803 tccagctccaccaggaggta tgggcgtctgggtactcatg ggacattgacctgtagtggg tatggagagtggaggaatgg
10883 tacaggcaggtgtgctggtg ctgacggacttgactccggc attgaccttggcttgcagtc tggtgttaaactaacaggga
10963 atgctgacaaaaagacagt tattaaaaccaagacaggat actgactttcccactcagccc attcccaagaatcccaaga
11042 cgtacaggaaatgtgcaaca gcagtgggaattgctgagtt gggggatgtgggtgagctgt gtgctcccagggaatttgg
11123 gaaattccctccgttgaaa tgctgtcagggtctgagcct tggaggtgtctttgggtgtgc tgtgctccccagctaagcag
11203 ctaacagtcctctcttacctg ccttgtcctcaccttgcccc accctgggttgggcctctcg ttcactccctgctgggtcac
11283 cagtacttcagtgcaggtct cagcttgattcttggtggag agagagaaagttgataaatc agggtgcctgtcagccggaa
11363 atttgggtgtgtcctgaagg caccaatggggggccctccct tctggaggtggctttaggaa gggggtttctgggtcttgagg
11443 cctccttacagtttcttagc tccatgggagagaagtgagg agttgggtatcgtcacccca gcatgaatctctggtcacct
11523 ctcagcatgcactgtccagc ctgatctttgagtgccataa aagaacagaattatcctctc agagcacttcatttcccgct
11603 agcacagtgggtacagagac aagctgcccagactcccagc gagggactagttgagcccca gcatgggactagttgagcta
11683 gacctgatacagtcccagag agcctcgttgaggaagcttt gggaaaattcacccagcatt tcagccaggactggaggaaa
11763 aggtgattatgggaaagaga gcagtcaagaccccaggctg taggacacaggatacaaact gagagctaccggataggagt
11843 aggttttagtcacaatctct cctgtccgccctaccctcca ggagacattgcaccttgtag aacagctgccccggagtcca
11923 cctttgggcccccctgggta gctcagtagtgtcagcatcc tctcattgacatcagtcagg ttacacagtggggcagctaa
12003 tgtgaaggcgctaggctggg aagccagctacttgggaaaa ctaggttgttcctggtaggc cctagcaggaaggcagttcc
12083 tcctttcttggtggcttta ggggtctttggaagctttga atgttccctcagctcgttgg tgaagcaggccctcctggta
12163 ctgtggtgtttgtcttcgaa gagtgaaggcattggaagta aagactgatggggcgccttc ccaggatgctttgcttcttg
12243 cgctggcttacagagctctc ttgctacctagtgccttgac tttgaacaccagattcagtc agggaacaggagtagaggtc
12323 ttgccttgctgagcccctgc gcactgcaggaaaagactcc tctgagtggagcctttcctc ctcaggtgactgctttcaaa
12403 gtacagcagcctctgagggg gaagtgtcatttgacattgt ggtagttcttggggtccctg gatacagatgtcatgcccag
12483 atcataggtctgtttgtaca gagggaggcgagttctgtag ctcagagtcctcagtacccc agagttgtggctctagggt
12563 gagaggagaagactacagcc cttcaatcacaggtctgacc tgtgggtaggggtagatctc ttgcatactatgaacctgtt
12643 tgaaaccctgggtatttgc tgtggaatagagtcttggtt gggtaagaatggtggatgtt tatcttggtgtgactctcgg
12723 gtgggggtgggggatatgtc cctgtctttcccaatgtagt atgctgagtggacagagacc gtgtgactgaagcctgggct
12803 cctggaacaggtgtgtgttg gtggggggtggggcgcaact atctgggatccagactgctt gggaatggctgtgaccagc
12883 tcctttgataacagcagctc tttgtcactggatgttgtga ctaatgggacttgttgattc agttactcggctcccaccca
12963 cagacgccgggcttctgtt gtggcaccaggcagctgcag acggcccacaagtttgcctc gctttcccactccacgaagg
13043 taagttcccagcactgccca aattagagacttgtgagtgg tccctcataccccactccc tgaggcttctcctggaaggc
13123 ctggaatggggcactgggtg tgtacgtgctgtggtttctg ttagggtcaagacaggctg tttcttacctggctcgtacc
13203 tccaagtttccaggtgatga gtcctgattttttgaagtgaa ggaatccatttaatatcaaa attctgtgaccttaaatttt
13283 tttcttttattatgtgtcat ttcatatgtacgcatatttt tttgtctgtgtgtgtgacatg cttgtggcgatcagaggaca
13363 cttcagaaagtcagttctct cctgccgtgtgggtcctggg gaatcaaatccaagttgtca ggctttatcctgaaaataaa
13443 aagtagacagcccttgggat ccaaagcttcttagggctgt gtgtcttagacaccaccagt gttgcacagctggtaacatg
13523 acagtgtcctggagtgctga ttggaagccacaggcctctg tgcagggcggtagacttcca gggtacggggcaggtgggcg
13603 ttctctacaaaaaccttgta atcgcggacgtcttggagat gcccctaggtatcatgatt ttggtgtgtgacacagctga
13683 actgtcttcatactcaggat atcatgaagtgctggggtgc agaccactctcagcctcagg cagccaggacccggggctcc
13763 atcagattgcggtgactacc acagagggtggccttccttc cggtcagtgtgggtgtggga gctggcaggaagtggctcca
13843 ggcttcctttaagcatcctc tgcccacagcccccaaacatg ttctttggcaatggcttgca actagaggtgaactctctcc
13923 tgtactatgtcctgacccac gctgctgcatctattatacc tttcacacgcgtgatgggta cccagcggggctgctaggca
14003 gggttaagcactcatcttgt ttcctggtgctgaagctgtg gtaaagaaactgaggccatt ttcccttgagagagatggtc
14083 tcagccaggtctttctcggc ctggggagccggaagaaag gatgtactacagtgagtgga cacttgttggctgatggcct
14163 tggtaggtccttcaccctgg gaagtgctgtttcttatctg ttagagatgctgacctcagc aggactggaggaactgcatg
14243 ggaggtgtaggaatgaaagt gagtggggaaaattatctcc agccctaggaagtctgagg cctgtgtccccttgtcctg
14323 gactgggcccctgccttggg tgtctgtccagggtctttgc tctacagcccagcggatgg ccaaagtagacgagtcaact
14403 ggtcctttcttcaccctgt gtccacttctcatgtatcta ccttcataatccttctaggt aaaacaagcctctaactttg
14483 ggttttcaaatcagccagct tccaggctcgatagtacgaa ccatgaaaatctttcttacc atgaggttgtttttctagtgt
14563 gtgtgtgtgtgtgtgtgtgt gtgtgtgtgtgtgtgtgt gtacgtacacatatgtacct ctatcagtgtgctgtgcgtg
14643 taccacagcagactcgtgag gaggtcaggcaaactttata aaaatcttttttttttgctt cacttgagtcccagggtcac
14723 acagtggcaagtgctgagct ctgttctctgttcttgattt gttttgtgagcagctgatgt tcttaaggcttgcggagggg
14803 aaaggtagggctggcttgct tcttcccgagtggcggtca atccctagacatctctaagc cgtggccacacgtcctggaa
14883 ggaccaggtcagaagtgat actgagatgccctgtgagc cctctcgaacacacagggtt gtaaatagtacctgattgtt
14963 acattggagactcgtcagct gggtggagtcctggttcaga gggagttattcctccccca catttcttctcttctggggc
15043 tgaagtctcttccttcctta cctgtgatgctgtcatgata ggtcccagctgagagtggag gcggggcagtcagggagctg
15123 cttctctttgcttagcaggg gttggagacttggggtgtag gggtcttggctcccccttccc tgccctggacctggtttctg
15203 gtttcagcagagattcgttc tagaaacttgttgcgtaaac aagatcacaaagcgataagg ttgagcaaaaccaagggaa
15283 caaattgcttccctgtgaag acccaatcttagctcttaga gaagccctccctttttggaaa ttgctgactttcagggcttc
15363 tctgtggaggaaagaggcta gccgccgtatgtttgcctgg attccaataaatctttgcgg ccttggctacccttgttga
15443 acaaggtggcactcctaat gcgtgcctcaggtggtctga gacctctaccccatctccag cttttccttcctatggaggg
15523 agtcagtgggttaggagaga atggagttgagtcctggaat gaggaggaagctatgaactc ggggcctgttcctgtctggt
15603 gggtgctcttctccgccgct gaaggaggcagccgcaggga agactaccacaggaatccga gtaccacctggagcagtgta
```

Figure 2 (Cont.) Sheet 4 of 6

```
15683 tacaggatgtgggctgatgt  gtggtaagggcatgatgggc  tgatgtgtggtaagggcatg  ggatctgattgctctgtgga
15763 tgggccacaggggaaatttt  gagtgtctactgcagtagtt  ctcaacctgtgggttgtgcg  cccccttggtgggagttacat
15843 attagatatttacattatga  ttcataactgctagcaaaatt acaattgtgaaagaaccaag  aaatcaccgcagcatgagaa
15923 cctgtattaaagggtcacgg  tgttaggagggttgagagcc  actcatcctctgggtctagg  ccatggcgggctgtaactgc
16003 tctctggagttaagccacag  tgaaccagctgtccttgcag  atggacttgtggaggctcca  aacctttgtcccagggggaga
16083 agagcttgcttttgctttgt  acttttaaaggaagttcagt  ggtcttcgggccttgtggct  gctgtgtgtggaagtgcccc
16163 tgtacaataagctgtataga  tcgtgtacaactgcagtttt  cctccgtgggtccaccaacc  actcctgactccacggatga
16243 gtgaggccagtagggctgtg  tgtgggtccctaggccaagc  atcctgaccacgatgagcc  tcagctagaccactctggat
16323 ctttagcagaggctcctaga  gagctggctggcttcctcct  gcttcttttctcttaaaac  ttcgtctcaatcggaagctc
16403 ctctgtgcacgtgacctcca  ggcctgggggtcgccacaaa  tcccctcatcacaagacgag  cagctcgcatgagggacacg
16483 acacttgttacctaccaggc  tgtggggttttttgttggttg gttgttttgttttgttttgt  ttttttacttgtacagaagt
16563 gttgtgacatcagatgtcag  ctgttagtgctggcaccatt  ttacaggtagggaactgagg  ctgtaagatgtgtagtgaca
16643 tcgctaaggccactcagttg  gtgaggccttaccaaggtca  ggtctttggagccttttgct  gaaccatgtacttctatctc
16723 tgtttggttgaaacaaagtc  tatatggctctggctagcct  ataaccccatatgtagacga  ggctgacctcgaatacactg
16803 cagtcttttatgtctgcctt  ctgggtggcaggattgaagg  catgtgattcctcctaactg  tacactttaaaaaaaaaatc
16883 attctttgttctggtctgtg  ccagggccttgtaagatgtt  ctgtgctgagctgggctatt  tgggttagtctcattgctga
16963 gcagggccctgtatcttcc  ttctctgtcacttgcttacc  tgggtcttcctcctgcacta  gctatcctagaaccagtact
17043 gagagcaactatgggcccaa  ctctgccccttgcccagcct  gcttagctggggcggtgtt  ccacttcctgcccaagtcc
17123 tgtgggactgtgtttgtact  ccaccacttcagttccttg  gagctggagcaggccaggcg  gctgcattcctgcagctgct
17203 gttgccagggagagcccatc  ccattcacttcagtctcctt  aatgtagaagccttgtcgaa  ttagcttccactgtccccaa
17283 cccaagagtaccctgtcctt  tcttcactaagaaggccaga  atacagtccttcctgtgggct gataagacaggccttgggac
17363 aaggcctgggaccacactgt  gtgggcanagctgcttcagc  accgatggctcctccatgcc  aagcttggctctgcttctca
17443 cagttgagacttctgtgcgc  acaccactgtctagctcag  ctggacctgatctttcttta  aatgtatagatttggggtg
17523 gggtgtgctgaaagctccca  ctgatgccccaagcctgagt  ctcagagtatgatcaattga  tggctttcatgggtatcaca
17603 gcttctgttcccaggtcaga  ctccctgaccagtcagagca  tcctgggggttagacaatgtc cccgtcacttgtgcctccac
17683 ctggcaccaggctatgatgt  tatggcattgagggtatgag  aaggaccaggggtttcccag  agttacgcccaggcgcacag
17763 gcaattgtttcctacatgtg  tggctggaatggttgggtga  gccttttcagctgctacaa  taggaaccaggggatactgg
17843 gcattgaccaaggcatatct  catacccttttcttatcttt  ctgcagCAAATTGTGGCTGT AAATGTTCCTCCTGAAGATC
                                                                GlnIleValAlaVa  lAsnValProProGluAspG

18923 AGGATGGCTCTGGGGATGAC  TCTGACAACTTCTCTGGCTC  TGGCACAGgtaagactgacc  cagaacactgagatggcata
      lnAspGlySerGlyAspAsp  SerAspAsnPheSerGlySe  rGlyThrG

18003 gatcatggctggagtggtga  gcaggcagtcaccagcttt  tagtgaacccccttcttctc  ccatcccatccttagccatt
18083 ggagtcaggacagtgccaaa  aggaagaatggtatccagct  gcaagccactcagctaagag  aaactctcagagaaatgaag
18163 gggttccaccaggccatggg  cagccactagagccaaccct  tggaggagtttgactccact  gagccttggtgtggtgtttc
18243 catctgtgagatgggaatac  tttgcccaagagcctgttag  aagctgtaggaagcacagag  tcggctaggtatagatttgc
18323 tctcacctccatctctcgat  accagttctctgcagagctc  gggttgtgggagggtggg  ggggtgagggagaaggctg
18403 tgagctgcagctagccagag  gggtctcccagaagaatggg  gagagctaagaagaaagtt  gaggtcacagtgggaaggag
18483 accagagcaaagggttggaa  ggtaggtaaaatgcagccgt  gtattcttgggagccttagg  ccttgggcaagagggtagaa
18563 gaggtgtttgtcctgggctg  cagtcctgtatcagctctgg  tgtcttggcccacgctcaca  gcaggatcccttcccagatt
18643 cccgagaatttctcacagtt  cagagagcacgctacttgta  ggcaggtgaggctgcaaagg  acagcttttctggcctaatt
18723 ttcaaagtgagttcagcctt  tgctaggtcacctttggggt  ctcagaaggcttcagctcct  ggtagagcatgaatcacgtc
18803 aggcgtgatgctggagacct  ctcctaccctgacacccaa  accccaccctctgaccctgc  agGTGCTTTGCCAGATACTT
                                                                                  lyAlaLeuProAspThrL

18883 TGTCACGGCAGACACCTTCC  ACTTGGAAGGACGTGTGGCT  GTTGACAGCCACGCCCACAG  CTCCAGAGCCCACCAGCAGC
      euSerArgGlnThrProSer  ThrTrpLysAspValTrpLe  uLeuThrAlaThrProThrA  laProGluProThrSerSer

19963 AACACCGAGACTGCTTTTAC  CTCTGTCCTGCCAGCCGGAG  AGAAGCCCGAGGAGGGAGAG  CCTGTGCTCCATGTAGAAGC
      AsnThrGluThrAlaPheTh  rSerValLeuProAlaGlyG  luLysProGluGluGlyGlu  ProValLeuHisValGluAl

19043 AGAGCCTGGCTTCACTGCTC  GGGACAAGGAAAAGGAGGTC  ACCACCAGGCCCAGGGAGAC  CGTGCAGCTCCCCATCACCC
      aGluProGlyPheThrAlaA  rgAspLysGluLysGluVal  ThrThrArgProArgGluTh  rValGlnLeuProIleThrG

19123 AACGGGCCTCAACAGTCAGA  GTCACCACAGCCCAGGCAGC  TGTCACATCTCATCCGCACG  GGGGCATGCAACCTGGCCTC
      lnArgAlaSerThrValArg  ValThrThrAlaGlnAlaAl  aValThrSerHisProHisG  lyGlyMetGlnProGlyLeu

19203 CATGAGACCTCGGCTCCCAC  AGCACCTGGTCAACCTGACC  ATCAGCCTCCACGTGTGGAG  GGTGGCGGCACTTCTGTCAT
      HisGluThrSerAlaProTh  rAlaProGlyGlnProAspH  isGlnProProArgValGlu  GlyGlyGlyThrSerValIl

19283 CAAAGAGGTTGTCGAGGATG  GAACTGCCAATCAGCTTCCC  GCAGGAGAGGGCTCTGGAGA  ACAAgtgagtggctttgcat
      eLysGluValValGluAspG  lyThrAlaAsnGlnLeuPro  AlaGlyGluGlySerGlyGl  uGln

19363 ttcctgggtggccactagtg  cctgcacctggccgcctaat  gtcctcattacagtgacagg  tgacagggtcccaccttcct
19443 cctgcccgaaacagactgat  tgcaagatcaggaggtgggc  gactccttagatgtcattca  ggagcttacagcagggtgaa
19523 tttttccgtcttagaccttca tgggaattttcacacaacaa  tgtgtacgttgtgtcactgg  aggcggtatctgtgtcttgg
19603 cctgccagggtcccaggtgt  gactgactgcattccttgac  agatgctggtataggttggc  tacgtctgatgggggtggca
```

Figure 2 (cont.) (Sheet 5 of 6)

```
19583 ggggatcccatcaggtatgg cactgctcaggctgctgctg cgtcagtggctccagctgac ctgatcccaacctacccttc
19763 tgtagGACTTCACCTTTGAA ACATCTGGGGAGAACACAGC TGTGGCTGCCGTAGAGCCCG GCCTGCGGAATCAGCCCCCG
          AspPheThrPheGlu  ThrSerGlyGluAsnThrAl aValAlaAlaValGluProG lyLeuArgAsnGlnProPro

19843 GTGGACGAAGGAGCCACAGG TGCTTCTCAGAGCCTTTTGG ACAGGAAGGAAGTGCTGGGA Ggtgagtcttctttcaggtg
       ValAspGluGlyAlaThrGl yAlaSerGlnSerLeuLeuA spArgLysGluValLeuGly G

20923 gagaggaggaggcaggtggt ggctctgaggtagcctgggt tgctggggtgaagcatcttt agcagcagggtggggaagga
20003 ggagggtcaattctactcca ggccacctcctaggctgtcc gtctagtctgggagagacta ccactgacccgtggagcta
20083 ctgatctgagcctgcctctg ttcactccctagGTGTCATT GCCGGAGGCCTAGTGGGCCT CATCTTTGCTGTGTGCCTGG
                                    lyValIle AlaGlyGlyLeuValGlyLe uIlePheAlaValCysLeuV

20163 TGGCTTTCATGCTGTACCGG ATGAAGAAGAAGGACGAAGG CAGCTACTCCTTGGAGGAGC CCAAACAAGCCAATGGCGGT
       alAlaPheMetLeuTyrArg MetLysLysLysAspGluGl ySerTyrSerLeuGluGluP roLysGlnAlaAsnGlyGly

20243 GCCTACCAGAAACCCACCAA GCAGGAGGAGTTCTACGCCT GATGGGGAAATAGTTCTTTC TCCCCCCACAGCCCCTGCCA
       AlaTyrGlnLysProThrLy sGlnGluGluPheTyrAla

20323 CTCACTAGGCTCCCACTTGC CTCTTCTGTGAAAAACTTCA AGCCCTGCCTCCCCACCAC TGGGTCATGTCCTCTGCACC
20403 CAGGCCCTTCCAGCTGTTCC TGCCCGAGCGGTCCCAGGGT GTGCTGGGAACTGATTCCCC TCCTTTGACTTCTGCCTAGA
20483 AGCTTGGGTGCAAAGGGTTT CTTGCATCTGATCTTTCTAC CACAACCACACCTGTTGTCC ACTCTTCTGACTTGGTTTCT
20563 CCAAATGGGAGGAGACCCAG CTCTGGACAGAAAGGGGACC CGACTCTTTGGACCTAGATG GCCTATTGCGGCTGGAGGAT
20643 CCTGAGGACAGGAGAGGGGC TTCGGCTGACCAGCCATAGC ACTTACCCATAGAGACCGCT AGGTTGGCCGTGCTGTGGTG
20723 GGGGATGGAGGCCTGAGCTC CTTGGAATCCACTTTTCATT GTGGGGAGGTCTACTTTAGA CAACTTGGTTTTGCACATAT
20803 TTTCTCTAATTTCTCTGTTC AGAGCCCCAGCAGACCTTAT TACTGGGGTAAGGCAAGTCT GTTGACTGGTGTCCCTCACC
20883 TCGCTTCCCTAATCTACATT CAGGAGACCGAATCGGGGGT TAATAAGACTTTTTTTGTTT TTTGTTTTTTGTTTTTAACCT
21963 AGAAGAACCAAATCTGGACG GCAAAACGTAGGCTTAGTTT GTGTGTTGTCTCTGAGTTTG TCGCTCATGCGTACAACAGG
21043 GTATGGACTATCTGTATGGT GCCCCATTTTTGGCGGCCCG TAAGTAGGCTGGCTAGTCCA GGATACTGTGGAATAGCCAC
21123 CTCTTGACCAGTCATGCCTG TGTGCATGGACTCAGGGCCA CGGCCTTGGCCTGGGCCACC GTGACATTGGAAGAGCCTGT
21203 GTGAGAACTTACTCGAAGTT CACAGTCTAGGAGTGGAGGG GAGGAGACTGTAGAGTTTTG GGGGAGGGGGTGGCAAGGGTG
21283 CCCAAGCGTCTCCCACCTTT GGTACCATCTCTAGTCATCC TTCCTCCCGGAAGTTGACAA GACACATCTTGAGTATGGCT
21363 GGCACTGGTTCCTCCATCAA GAACCAAGTTCACCTTCAGC TCCTGTGGCCCCGCCCCCAG GCTGGAGTCAGAAATGTTTC
21443 CCAAAGAGTGAGTCTTTTGC TTTTGGCAAAACGCTACTTA ATCCAATGGGTTCTGTACAG TAGATTTTGCAGATGTAATA
21523 AACTTTAATATAAAGGAGTC CTATGAACTCTACTGCTTCT GCTTCTTCTTCTCTGGACTG GTGGTATAGATATAGCCACC
21603 CTTTGCCCAAACCCTGGTAG CTCGGGGAAGCTTGGCTTAA GGCTGCACGCCTCCAATCCC CCAAAGGTAGGATCCTGGCT
21683 GGGTCCAGGGTTCCTCTGAT TTATTTGGTTTTGTTGTGTT GTGTTGTGTTTTTCTTTTGG CTAAACTTCTTTTGGAAGTT
21763 GGTAAGTTCAGCCAAGGTTT TACAGGCCCTGATGTCTGTT CTTCTAAATGGTTTAAGTAA TTGGGACTCTAGCACATCTT
21843 GACCTAGGGTCACTAGAGCT AAGCTTGCTTTGCAGGGCAG ACACCTGGGACAGCCTTCCT CCCTCATGTTTGCTGGGACA
22923 CTGCTGAGCACCCCTTGCTT ACTTAGCTCAGTGATGTTCC AGCTCCTGGCTAGGCTGCTC AGCCACTCAGCTAGACAAAA
22003 GATCTGTGCCCTGTGTTTCA TCCCAGAGCTTGTTGCCAGA TCACATGGCTGGATGTGATG TGGGGTGGGGGTGGGGTCAT
22083 ATCTGAGACAGCCCTCAGCT GAGGGCTTGTGGACAGTGT CAAGCCTCAGGCTGGCGCTC ATTCATATAATTGCAATAAA
22163 tggtacgtgtccatttggac agcagacactttggtgtact tgtgcagtctcttttggtc tggaccatgtccaactctat
22243 ctggttttggaatgggagc ctaactggcctgtgttctgg cttggtaccaaatagcaaca gtcagtggcatccttgccca
22323 ggccccagggcaggactatg ctcttgccatatccaggact cccgactttgcacctgtttt ccctcctgtgtgtagcatcat
22403 gaactccagctaggttgttc ctttccctggggtcaggagg attctgctgactctgaatgt caggatttgcttttgttctg
22483 tttgcttattgggcaattct caaccttcactagcaacagt ctcatgtgtcaggattacaa gtattgcttgcacattgagg
```

Figure 2 (Cont.)(Sheet 6 of 6)

wild type

tail-less

ecto

☐ ectodomain   ▨ transmembrane domain
▨ cytoplasmic domain

- FIGURE 3 -

- FIGURE 4 -

- FIGURE 5 -

- FIGURE 6 -

Ecto 15   Ecto 34   Ecto 2   Ecto 23

- FIGURE 7 -

- FIGURE 8 -

- FIGURE 9 -

- FIGURE 10 -

- FIGURE 11 -

- FIGURE 12 -

FIGURE 13

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6   A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 12162 (WÄRRI, ANNI, MAIJA ET AL.) 9 June 1994 cited in the application see page 8, line 5 - page 13, line 13 ---	1-22
X,P	JOURNAL OF BIOLOGICAL CHEMISTRY, vol.269, no.45, 11 November 1994, BALTIMORE, MD US pages 27795 - 27798 MARKKU MALI ET AL. 'SUPPRESSION OF TUMOR CELL GROWTH BY SYNDECAN-1 ECTODOMAIN.' see the whole document ---	1-22
X,P	WO,A,95 00633 (CHILDREN'S MEDICAL CENTER CORPORATION ET AL.) 5 January 1995 see page 37, line 17 - page 41, line 24 -----	1-22

☐ Further documents are listed in the continuation of box C.   ☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 November 1995	24.11.95

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Rempp, G

Form PCT/ISA/210 (second sheet) (July 1992)

1

| Box I | Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) |

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:   1-18
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-18 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

| Box II | Observations where unity of invention is lacking (Continuation of item 2 of first sheet) |

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [ ] As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest   [ ] The additional search fees were accompanied by the applicant's protest.

                           [ ] No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9412162	09-06-94	AU-B-	5564994	22-06-94
		CA-A-	2150714	09-06-94
		EP-A-	0671909	20-09-95
WO-A-9500633	05-01-95	AU-B-	7112994	17-01-95

THIS PAGE BLANK (USPTO)